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ABSTRACT
Coronaviruses are positive‐sense, single‐stranded RNA viruses with exceptionally
large genomes. The majority of the genomic RNA encodes non‐structural proteins
(nsps) necessary for viral replication. These nsps are translated as a large polyprotein
that is proteolytically processed by two or three virally encoded proteases of two
varieties: papain‐like (PLP) and picornavirus 3C‐like (3CLpro). Cleavage of the
polyprotein generates intermediates and mature nsps that modify host cell membranes
to produce double membrane vesicles (DMVs) upon which the nsps, also known as
replicase proteins, assemble to form the viral replicase‐transcriptase that synthesizes
viral genomic and subgenomic RNA. Of the sixteen replicase proteins, three (nsp3,
nsp4, and nsp6) are integral membrane proteins that are hypothesized to be involved in
DMV formation. One goal was to characterize the function of nsp4 in MHV replication.
Work presented in this dissertation demonstrates that nsp4 is subjected to N‐linked
glycosylation and that glycosylation of N176 is dispensable for viral replication whereas
glycosylation of N237 is not. Furthermore, mutation of N258 to threonine in nsp4
confers a temperature sensitive phenotype to MHV‐A59 infectious clone virus. This
virus (Alb ts6 icv) has a significant defect in replication when incubated at the non‐
permissive temperature of 39.5°C. Processing of the p150 intermediate (nsp4‐11)

xiv

is unaffected at the non‐permissive temperature; however, DMV formation is impaired.
Interestingly, mitochondrial morphology is altered in Alb ts6 icv infected cells at the
non‐permissive temperature, and replicase components nsp3 and nsp4 have increased
localization with the mitochondria at 39.5°C. Complementation studies suggest that the
ts lesion may affect the p150 precursor as well as nsp4. These data demonstrate a
critical role for p150 and/or nsp4 in the assembly of DMVs and the viral replication
complex.
The integral membrane protein nsp3 has been shown to encode the papain‐like
protease domains that cleave the N‐terminus of the polyprotein. In addition to
polyprotein processing and a potential role in DMV formation, nsp3 from MHV, HCoV‐
NL63, and SARS‐CoV has been shown to possess deubiquitinating activity. This activity is
known to negatively influence the induction of type I IFNs, which are potent anti‐viral
proteins secreted upon viral infection. Consistent with these data, the papain‐like
protease domains from these viruses were shown to inhibit the induction an IFN‐β‐
luciferase reporter as well as reporters dependent on the two key transcription factors
involved in type I IFN expression: IRF‐3 and NF‐κB. In contrast to MHV, the PLPs from
HCoV‐NL63 (PLP2) and SARS‐CoV (PLpro) were able to inhibit type I IFN induction
independently of catalytic activity albeit to a lesser degree than wildtype. Further
investigation into the mechanism of inhibition revealed that the PLPs associated with
and inhibited the dimerization of a key protein involved in IRF‐3 activation, stimulator of
IFN genes (STING). The PLPs can inhibit STING‐mediated activation and nuclear
xv

translocation of IRF‐3. These data suggest that the PLPs inhibit type I IFN induction by
deubiquitinating key proteins in the IFN induction cascade as well as associating with
and inhibiting the dimerization of STING thereby inhibiting the activation and nuclear
translocation of IRF‐3.

xvi

CHAPTER I
INTRODUCTION

CORONAVIRUSES: CLASSIFICATION, VIRION, AND GENOME
Coronaviruses (CoV) were first cultivated in the 1930s‐1940s (Beaudette and
Hudson, 1937; Cheever, et al., 1949; Doyle and Hutchings, 1946). Infectious bronchitis
virus (IBV) was isolated from chickens and propagated in chicken embryos (Beaudette
and Hudson, 1937). Mouse hepatitis virus (MHV) and transmissible gastroenteritis virus
(TGEV) were isolated from and propagated in mice and pigs repectively (Cheever, et al.,
1949; Doyle and Hutchings, 1946). Characterization of coronaviruses at the
ultrastructural level revealed a particle that is roughly spherical, about 100‐160 nm in
diameter, with bulbous projections that gave the virion a crown‐like or corona‐like
appearance (David‐Ferreira and Manaker, 1965; Domermuth and Edwards, 1957).
These viruses comprise a genus, the coronaviruses, within the Coronaviridae family. The
Coronaviridae, along with the Arteriviridae and Roniviridae, are within the Nidovirales
order. Coronaviruses have been placed into three serogroups based on antigenicity
(Siddell, 1995). Members of group I include the human coronaviruses (HCoV) 229E and
NL63 and a large number of animal viruses. Like group I, group II contains two human
coronaviruses, OC43 and HKU1 and a variety of animal viruses. SARS‐CoV, a highly
1

2
pathogenic human coronavirus, is most closely related to and is sometimes considered a
group II coronavirus. Finally, group III coronaviruses are primarily avian viruses.
Coronaviruses cause significant and economically important disease in cattle, poultry,
and pigs and severe disease in cats and humans (Fields, et al., 2007).
The coronavirus virion is depicted in Figure 1. The virus is enveloped with three
or four integral proteins spanning the membrane. All coronaviruses have the spike
glycoprotein (S), membrane (M), and envelope (E) while some group II viruses and
turkey coronavirus (group III) also contain a hemagglutinin‐esterase (HE) protein within
the viral envelope. Spike contains three domains: a short internal C‐terminal domain, a
transmembrane (TM) domain, and a large exterior domain that contains the S1 and S2
subdomains generated by proteolytic cleavage of spike. The S1 domain contains the
bulbous N‐terminal portion of spike, while the S2 domain comprises the stalk. Evidence
suggests that the stalk forms a coiled‐coil structure and oligomerizes as a trimer (de
Groot, et al., 1987; Delmas and Laude, 1990; Lewicki and Gallagher, 2002). The shorter
spike‐like protein found on some coronaviruses is the HE protein which is a disulfide‐
linked dimer (Hogue, et al., 1989). HE is not essential for viral replication and is
sometimes lost upon serial passage of mouse hepatitis virus; however, HE enhances
pathogenesis by increasing the neurovirulence of MHV‐JHM (Kazi, et al., 2005;
Yokomori, et al., 1991). The M protein, a triple‐pass TM protein, is the most abundant
protein in the viral envelope (Voss, et al., 2009). M protein interacts with both spike

3

Figure 1. The coronavirus virion. The virus is roughly spherical with bulbous
projections, which are the spike glycoprotein (S). Other integral proteins include
membrane (M) and envelope (E). Some coronaviruses also contain a hemagglutinin‐
esterase (HE) protein within the viral envelope. Within the virus is the genomic RNA
that is coated with N protein.

4
and nucleocapsid and facilitates virus assembly (de Haan, et al., 1999; Kuo and Masters,
2002). M protein may also be involved in the assembly of the viral nucleocapsid by
interacting with a packaging signal in the viral RNA (Narayanan, et al., 2003). Like M, the
E protein is a TM‐containing protein within the viral envelope. E protein has been
shown to assist in MHV virus assembly but is not absolutely required (Kuo and Masters,
2003). Inside the virion is a single‐stranded, positive‐sense RNA genome that among the
RNA viruses is extremely large averaging approximately 30 kilobases. The nucleocapsid
or N protein surrounds the viral RNA (Davies, et al., 1981; Kennedy and Johnson‐
Lussenburg, 1975; Macnaughton, et al., 1977; Macneughton and Davies, 1978). The
helical nucleocapsid, when released from viral particles, has a spring‐like appearance
with the coils approximately 14‐16 nm in diameter (Risco, et al., 1996; Sturman, et al.,
1980).
All coronaviruses have a similar genomic organization as shown in Figure 2 for
MHV, HCoV‐NL63, and SARS‐CoV, the three viruses discussed in this dissertation.
Encoded within the first two‐thirds of the genome are the non‐structural proteins (nsps)
and the final third encodes the spike, envelope, membrane, and nucleocapsid as well as
additional accessory open reading frames. The RNA genome is similar to cellular mRNA
in that it is capped and poly‐adenylated. The 5’ end contains a leader sequence that is
65 to 98 nucleotides long, which is then followed by an untranslated region (UTR) of
about 200 to 400 nucleotides in length (Masters, 2006). The translated region begins
with the non‐structural proteins, also called replicase proteins. These proteins

5

Figure 2. Genomic organization of MHV, HCoV‐NL63, and SARS‐CoV. A leader
sequence (L) is at the 5’ end of the genome (and all subgenomic mRNA). Two large
open reading frames encode the replicase or non‐structural proteins. The final one‐
third of the genome encodes the structural proteins spike, envelope, membrane, and
nucleocapsid as well as additional accessory open reading frames. The genome is
capped and poly‐adenylated.

6
are synthesized as a large polyprotein from ORFs 1a and 1b. The ORF1ab polyprotein is
generated by a ‐1 ribosomal frameshift between ORF1a and ORF1b. This frameshift is
induced by a stem‐looped pseudoknot and a slippery sequence at the junction between
ORF1a and ORF1b (Brierley, et al., 1989; Plant, et al., 2005). The large polyprotein is
processed by two classes of virally encoded proteases, the papain‐like protease(s) (PLPs)
and the picornavirus 3C‐like protease (3CLpro) (Baker, et al., 1989; Bonilla, et al., 1997;
Deming, et al., 2007; Denison, et al., 1995; Denison, et al., 1998; Dong, et al., 1995;
Kanjanahaluethai and Baker, 2000; Kanjanahaluethai and Baker, 2001;
Kanjanahaluethai, et al., 2003; Schiller, et al., 1998). The cleavage patterns of the PLPs
and 3CLpro for MHV, HCoV‐NL63, and SARS‐CoV are depicted in Figure 3. Cleavage of
the polyprotein generates multiple intermediates and ultimately mature nsps.
Following ORFs 1a and 1b are the structural proteins and accessory open reading frames
that are translated from a nested set of 3’ co‐terminal subgenomic mRNAs (Weiss and
Leibowitz, 1983). The number of accessory genes varies; however, all coronaviruses
have the 5’‐Pol‐ S‐E‐M‐N‐3’ overall genomic organization. Another UTR of about 200‐
500 nucleotides is present at the 3’ end that is followed by a poly(A) tail (Fields, et al.,
2007).

7

Figure 3. Proteolytic processing of polyprotein 1ab (pp1ab). The N‐terminal portion
of the pp1ab polyprotein is processed by one or two papain‐like proteases. The
remaining polyprotein is processed by the picornavirus 3C‐like protease (3CLpro).
Processing liberates 16 nsps that assemble to form the viral replication complex,
which synthesizes genomic and subgenomic RNA

8
CORONAVIRUS REPLICATION
Attachment and Entry
Coronavirus replication is outlined in Figure 4. Coronaviruses attach to target
cells by engagement of the spike glycoprotein with a receptor on the surface of the host
cell. Binding of spike to the receptor induces a conformational change within spike
which exposes the fusion domain (Gallagher, 1996; Zelus, et al., 2003). Fusion of the
viral envelope with cellular membranes releases the nucleocapsid into the cytoplasm.
Membrane fusion is likely driven solely by interaction between spike and the target cell
receptor as exogenously expressed spike can induce cell‐cell fusion in receptor
expressing cells (Boyle, et al., 1987; Vennema, et al., 1990). Depending on the virus,
fusion occurs at the plasma membrane or in endosomes. Some strains of MHV, bovine
coronavirus (BCoV), and infectious bronchitis virus are believed to fuse at the plasma
membrane as optimal cell‐cell fusion occurs at neutral or slightly alkaline pH (Kooi, et
al., 1991; Li and Cavanagh, 1992; Payne, et al., 1990; Sturman, et al., 1990; Weismiller,
et al., 1990). Evidence suggests that SARS‐CoV fuses with the endosomal membrane as
agents that inhibit endosomal acidification also inhibit SARS‐CoV entry (Yang, et al.,
2004). Low pH was not required for cell‐cell fusion mediated by spike, however. The
requirement for acidic pH has been shown to be necessary for cathepsin L activation,
which then cleaves spike into a fusion‐competent form (Matsuyama, et al., 2005;
Simmons, et al., 2005). Upon delivery of the nucleocapsid into the cytoplasm, the RNA
is uncoated and ready for translation.

9

Figure 4. Coronavirus replication cycle. Coronaviruses attach to the target cell via
interaction between the spike glycoprotein and a cellular receptor. Membrane
fusion delivers the genomic RNA into the cytoplasm, which is translated to produce a
large polyprotein that is processed by virally encoded proteases into mature
nonstructural proteins or nsps. Coronavirus infection induces the formation of
double membrane vesicles or DMVs within the cell. Viral intermediates and/or
mature nsps assemble on DMVs to form the viral replication complex that
synthesizes genomic and subgenomic RNA. Translation of the structural proteins
produces the components necessary for virion assembly. The components bud into
the ER Golgi intermediate complex (ERGIC) where virus is assembled. Mature virus
accumulates in smooth‐walled vesicles and exits the cell by exocytosis.
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Assembly of the Viral Replication Complex and mRNA Transcription
Translation and processing of ORF1ab generates proteins necessary to form the
viral replication complex. Processing by the PLPs and 3CLpro liberates approximately 16
mature non‐structural proteins that, with the exception of nsp2, are all required for viral
replication (Graham, et al., 2005). While the functions of some replicase proteins are
still unknown, several nsps have characterized enzymatic functions. nsp3 contains
either one or two papain‐like protease domains, which cleave the N‐terminal portion of
the polyprotein, have deubiquitinating (DUB) and deISGylating activity, and adenosine
diphosphate‐ribose 1’‐phosphatase activity (Baker, et al., 1989; Barretto, et al., 2006;
Barretto, et al., 2005; Clementz, et al., 2010; Kanjanahaluethai and Baker, 2000;
Kanjanahaluethai and Baker, 2001; Lindner, et al., 2005; Lindner, et al., 2007; Snijder, et
al., 2003). Another cysteine protease domain is encoded within nsp5, which bears
similarity to the 3C protease of picornaviruses (Gorbalenya, et al., 1989; Lee, et al.,
1991). This protease, termed 3CLpro or Mpro (main protease), is responsible for the
majority of the polyprotein cleavage primarily the C‐terminal portion of the polyprotein
(Deming, et al., 2007; Denison, et al., 1995; Denison, et al., 1998; Lu, et al., 1998; Lu, et
al., 1995). The RNA‐dependent RNA polymerase (RdRp) activity is encoded within nsp8
and nsp12 (Cheng, et al., 2005; Imbert, et al., 2006). nsps 13‐16 have been found to
have helicase (nsp13), exonuclease (nsp14), endoribonuclease (nsp15), and
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methyltransferase activity (nsp16) (Bhardwaj, et al., 2004; Decroly, et al., 2008; Ivanov,
et al., 2004a; Ivanov, et al., 2004b; Ivanov and Ziebuhr, 2004; Ricagno, et al., 2006;
Ziebuhr, 2005). nsp7 and nsp8 can form a hexadecameric complex that is capable of
binding RNA (Zhai, et al., 2005). Also capable of binding nucleic acid are nsps 9 and 10
(Matthes, et al., 2006; Sutton, et al., 2004).
The viral replication complex or replicase assembles on cellular membranes
modified by viral infection. Three of the nsps (nsp3, nsp4, and nsp6) are TM‐containing
proteins that are involved in membrane rearrangements during coronavirus infection
(Clementz, et al., 2008; Gadlage, et al., 2010; Oostra, et al., 2008; Oostra, et al., 2007).
Coronavirus infection induces the formation of double membrane vesicles (DMVs),
which are the sites of replicase assembly and thus viral RNA synthesis (Brockway, et al.,
2003; Gosert, et al., 2002; Snijder, et al., 2006). The positive‐stranded genome is first
turned into a negative‐stranded RNA molecule that then serves as the template for the
synthesis of multiple subgenomic mRNAs that have identical 3’ ends but have different
portions of the 5’ end (Hofmann, et al., 1990; Sethna, et al., 1991; Sethna, et al., 1989).
The generation of a nested set of 3’ co‐terminal subgenomic RNAs is a hallmark of the
Nidovirales order (Nido, Latin for “nest”). Analysis of the viral mRNA revealed that the
5’ end of each mRNA had an identical leader sequence to the leader sequence found at
the 5’ end of the genomic RNA (Brown, et al., 1984; Lai, et al., 1984; Sethna, et al., 1991;
Spaan, et al., 1983). This could occur through processing full length genomic RNA
similar to mRNA splicing or by transcription of the 3’ end followed by dissociation of the
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polymerase and re‐association at the leader. Experimental evidence supports the latter,
which has been termed the discontinuous transcription model (Jacobs, et al., 1981). The
most telling experiment in support of a dissociable transcription process is the
observation that leader sequences from two different strains of MHV can freely re‐
assort. mRNAs from a given strain had nearly equal use of leaders derived from either
strain (Makino, et al., 1986). Two models to explain the process of discontinuous
transcription of coronavirus subgenomic RNA have been proposed: the leader‐primed
model and the negative‐stand model (Lai, 1986; Sawicki and Sawicki, 2005).
In the leader‐primed model, the replicase, using a full length negative strand
template, transcribes the leader sequence then dissociates. The transcriptase then re‐
engages the template further downstream at intergenic (IG) sequences or transcription‐
regulatory sequences (TRSs), which are found at the beginning of each ORF and have
complementarity (7‐18 nucleotides) to the leader (Thiel, et al., 2003). Another variation
of the leader‐primed model is similar to the B cell recombination excision circles (BRECs)
system where the viral RNA loops around itself joining the TRSs and the leader.
Transcription then proceeds linearly skipping the looped out region to generate the
subgenomic RNA (Lai and Cavanagh, 1997).
In contrast to the leader‐primed model, the negative‐strand model suggests that
discontinuous transcription occurs during negative‐strand synthesis. According to this
model, the viral replicase, using the genomic RNA as a template, transcribes a
complementary negative‐strand RNA beginning at the 3’ end of the template. Upon
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reaching a TRS, the replicase stalls, dissociates, and re‐engages the genomic template at
the 3’ end of the leader. Current evidence supports the negative‐strand model as
subgenomic negative‐stranded RNA and subgenomic negative‐strand RNA intermediates
are found in coronavirus infected cells (Sawicki and Sawicki, 1990; Sethna, et al., 1991;
Sethna, et al., 1989). Furthermore, leader switching can occur during co‐infection
generating full length genomic RNA from one strain that has the leader from the other
strain. These data suggest that genomic RNA replication may proceed in a discontinuous
manner as well (Makino, et al., 1986).

Assembly and Dissemination of Virus Particles
Subgenomic mRNA transcription generates the templates necessary for
expression of the structural proteins. Spike is translated on the rough endoplasmic
reticulum (RER) and subjected to N‐linked glycosylation, which is necessary for proper
maturation of spike as treatment of infected cells with tunicamycin (agent that inhibits
N‐linked glycosylation) results in assembly of spikeless virions (Holmes, et al., 1981).
Spike oligomerizes into a trimer and transits from the ER to sites of virus particle
assembly via interaction with M and E protein (Delmas and Laude, 1990). Some spike
transits to the plasma membrane and induces cell‐cell fusion leading to cytopathic effect
(CPE) in the form of syncytia. In addition to glycosylation, spike is palmitoylated on
cysteine residues (Bos, et al., 1995; Petit, et al., 2007; Shulla and Gallagher, 2009). Like
spike, M protein is also made on the RER and is glycosylated. In some viruses, M is
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subjected to N‐linked glycosylation (groups 1 and 3 and SARS‐CoV) and, in others, O‐
linked (MHV and BCV) (Lai and Cavanagh, 1997). M protein is found in both the Golgi
and the ER/Golgi intermediate complex (ERGIC) (Klumperman, et al., 1994). E protein,
following translation and palmitoylation in the RER, accumulates in the ERGIC (Corse
and Machamer, 2002; Opstelten, et al., 1995). Nucleocapsid associates with cellular
membranes and DMVs where it coats viral genomic RNA and then localizes to sites of
viral assembly late in infection (Brockway, et al., 2004; Sims, et al., 2000).
Virus budding occurs primarily into smooth‐walled vesicles of the ERGIC and to
some extent in the RER (Goldsmith, et al., 2004; Klumperman, et al., 1994; Tooze, et al.,
1984). Assembly of virus‐like particles (VLP) occurs in M protein expressing cells
suggesting that this protein is necessary and sufficient for VLP formation; however, in
the absence of E protein, VLPs have aberrant morphology suggesting that E protein
plays a role in efficient VLP assembly (Bos, et al., 1996; Kuo and Masters, 2003;
Vennema, et al., 1996). Following maturation of the virion in the Golgi, virus particles
are released from the cell by fusion of the smooth‐walled vesicles with the plasma
membrane.

CORONAVIRUS REPLICASE INTEGRAL MEMBRANE PROTEINS
The mechanism of DMV formation in coronavirus infection is currently poorly
understood. The integral membrane proteins from the non‐structural region are likely
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candidates for involvement in alteration of host cell membranes. For instance, ectopic
expression of nsp2 and nsp3 from equine arteritis virus (EAV), a member of the related
family Arteriviridae, is necessary and sufficient to induce DMV formation (Snijder, et al.,
2001). These proteins in EAV are homologous to nsp3 and nsp4 in coronaviruses. The
primary role of nsp3 in coronavirus infection is cleavage of the polyprotein by the
papain‐like protease domains encoded within this integral membrane protein; however,
nsp3 may be involved in membrane rearrangements as well. To date, no enzymatic
functions have been elucidated for the other two integral membrane proteins, nsp4 and
nsp6.
The membrane topology of nsp4 and nsp6 in MHV and SARS‐CoV has been
elucidated. nsp4 contains four TM domains with a large luminal region between TMs 1
and 2 (Figure 5) (Oostra, et al., 2007). Using reverse genetics in MHV, the amino
terminal portion, as well as specific asparagine residues, have been shown to be critical
for proper function of nsp4 (Clementz, et al., 2008; Gadlage, et al., 2010; Sparks, et al.,
2007). nsp6 contains six TM spanning domains (Baliji, et al., 2009; Oostra, et al., 2008).
All integral membrane nsps have a Nendo/Cendo topology placing the active domains of
coronavirus nsps in the cytoplasm, particularly the protease domains and all the
cleavage sites (Oostra, et al., 2008). Interestingly, nsp3 and nsp6 for both MHV and
SARS‐CoV were predicted to contain an additional TM domain via bioinformatics. These
predictions yielded an odd number of TM domains, which is in conflict with the known
Nendo/Cendo topology. Experimental evidence ruled out the use of one of the
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Figure 5. Schematic diagram of nsp4. Non‐structural protein 4 contains four
transmembrane domains. Between TM1 and TM2 is a large portion of nsp4 that
contains two asparagines that are subjected to N‐linked glycosylation. Another
asparagine residue (N258) when mutated to threonine induces a temperature
sensitive defect in MHV replication.
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predicted TM domains; however, these observations raise questions about the role of
the non‐membrane spanning hydrophobic domains in DMV formation and viral
replication.

ROLE OF NSP4 IN MHV INFECTION
Since the homolog of coronavirus nsp4 in EAV (nsp3) has been shown to be
involved in DMV formation, nsp4 is predicted to be involved in coronavirus induced
DMV formation. One goal of my dissertation work was to expand current knowledge of
the function of nsp4 in murine coronavirus infection. Analysis of mutants of MHV has
confirmed a role for nsp4 in biogenesis of DMVs. Bioinformatic analysis has identified
two consensus NxS N‐linked glycosylation sites in the large luminal portion of nsp4, and
nsp4 has been subsequently experimentally verified to be subjected to N‐linked
glycosylation (Clementz, et al., 2008; Gadlage, et al., 2010). The two asparagines
subjected to N‐linked glycosylation are N176 and N237 (amino acid numbering from the
beginning of nsp4) (Clementz, et al., 2008). Mutation of N176 to alanine in reverse
engineered MHV has no effect on viral replication; however, mutation of N237 impairs
both replication and DMV formation suggesting that nsp4 is involved in replicase/DMV
assembly and that glycosylation of N237 is critical for the proper folding or function of
nsp4 (Clementz, et al., 2008; Gadlage, et al., 2010).
A role for nsp4 in DMV formation is further supported by the generation and
characterization of a temperature sensitive (ts) mutant of MHV with the ts lesion in
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nsp4. The mutation was initially identified by sequencing a large panel of chemically
mutagenized ts mutants of MHV that are unable to synthesize RNA at the non‐
permissive temperature (Sawicki, et al., 2005). Since other mutations were present
throughout the genome, the implicated mutations could not be definitively concluded
to be causative. Using reverse genetics, the putative ts lesion (N258 to threonine) was
introduced into otherwise wildtype MHV and this mutation alone was sufficient to
induce temperature sensitivity (Clementz, et al., 2008). Kinetic analysis of this mutant
showed that, at the permissive temperature (33°C), wildtype MHV and the N258T
mutant (referred to as Alb ts6 icv or simply ts6) grew indistinguishably. However, when
grown at the non‐permissive temperature (39.5°C), the ts6 virus generated titers of
virus that were five orders of magnitude reduced compared with wildtype MHV
(Clementz, et al., 2008). Transmission electron microscopic (TEM) analysis revealed that
fewer DMVs were formed in ts6 infected cells when shifted to the non‐permissive
temperature. Furthermore, localization of nsp4 affected the subcellular localization of
nsp3 supporting the notion that nsp4 is involved in replicase and/or DMV assembly
(Clementz, et al., 2008).

MULTIFUNCTIONAL INTEGRAL MEMBRANE NSPS
Aside from its predicted role in DMV formation and known role in polyprotein
processing, nsp3 has been shown to have other catalytic functions. Recall that the nsp3
protein encodes papain‐like protease domain(s). Most coronaviruses, except SARS‐CoV
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and IBV, encode two papain‐like protease domains within nsp3 designated as PLP1 and
PLP2 (PLpro for SARS‐CoV and IBV). The PLPs cleave the amino terminal end of the
polyprotein to liberate nsps1‐4 (liberation of nsp4 requires cleavage of the C‐Terminus
by 3CLpro). Based on similar structural features between SARS‐CoV PLpro and a cellular
deubiquitinating enzyme, herpesvirus‐associated ubiquitin‐specific protease (HAUSP),
PLpro was predicted to have deubiquitinating (DUB) activity (Hu, et al., 2002; Sulea, et
al., 2005). Furthermore, the consensus sequence LxGG recognized by cellular DUBs was
predicted to be the same as the recognition sequence in the polyprotein (Thiel, et al.,
2003). Subsequent studies into this prediction revealed that PLpro is in fact able to
deconjugate ubiquitin (Ub) (Barretto, et al., 2006; Barretto, et al., 2005; Lindner, et al.,
2005). DUB activity has also been shown in the PLPs of human coronavirus (HCoV) NL63
PLP2 and MHV PLP2 and predicted in HCoV‐229E (Barretto, et al., 2005; Chen, et al.,
2007b; Clementz, et al., 2010; Zheng, et al., 2008). The Ub‐like moiety ISG15 (interferon
stimulatory gene of 15 kDa) is structurally similar to diubiquitin and has the same LxGG
cleavage signal as Ub and the polyprotein suggesting that PLPs may be able to
deconjugate ISG15 (deISGylation). Consistent with this hypothesis, PLpro from SARS‐
CoV and PLP2 from HCoV‐NL63 have been shown to possess deISGylating activity;
however, it is currently unclear what effect, if any, the deISGylating activity has on viral
replication (Clementz, et al., 2010; Lindner, et al., 2007).
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DUB ACTIVITY AND INNATE IMMUNITY
The Innate Immune Response
Among the many roles for ubiquitination in the cell, conjugation of Ub to
signaling molecules has been shown to influence signal transduction (Haglund and Dikic,
2005). Of note for viral infection, ubiquitination has been intimately tied to regulation
of the innate immune induction of type I interferons (IFNs) (Bhoj and Chen, 2009;
Bibeau‐Poirier and Servant, 2008; Liu, et al., 2005). There are two main classes of type I
IFNs, interferon alpha (IFN‐α) and interferon beta (IFN‐β). IFNs are potent anti‐viral
proteins that are induced by recognition of viral pathogen‐associated molecular
patterns (PAMPs) by pathogen recognition receptors (PRRs), which come in two main
varieties: the membrane bound toll‐like receptors (TLRs) and the cytoplasmic RNA
helicases (Kawai and Akira, 2006; Koyama, et al., 2008). The importance of this pathway
in suppressing viral infection is evidenced by the wide variety of viruses and the vast
array of ways viruses employ to antagonize IFN induction and signaling (Bowie and
Unterholzner, 2008; Katze, et al., 2002; Sen, 2001). The signaling cascade is depicted in
Figure 6. Stimulation of PRRs induces activation of a large number of signaling adaptor
proteins, which ultimately turn on transcription factors necessary for type I IFN
expression. Binding of IFNs to their cognate receptor induces the activation of the IFN
signaling cascade that results in the upregulation of a large set of genes known as
interferon stimulated genes (ISGs), which establish an anti‐viral state in the cell by

21

Figure 6. Type I IFN induction and signaling cascade. Sensing of viral PAMPs initiates
the activation of the type I IFN induction cascade that results in the activation of IRF‐
3 and NF‐κB, which cooperatively activate IFN‐β transcription. IFN‐β protein is
produced and secreted from the cell. Engagement of the IFN receptor by type I IFNs
stimulates the IFN signaling cascade that ultimately results in the upregulation of
ISGs that induce an anti‐viral state in the cell to limit viral replication.
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generating an environment that is hostile to viral replication (Meylan and Tschopp,
2006; Platanias, 2005; Samuel, 2001; Seth, et al., 2006; Theofilopoulos, et al., 2005).

Activation of NF‐κB
The primary transcription factors necessary for type I IFN expression are
interferon regulatory factor 3 (IRF‐3) and nuclear factor kappa‐light‐chain‐enhancer of
activated B cells (NF‐κB). Activation of the RNA helicases stimulates their binding to the
adaptor protein MAVS (also known as VISA, CARDIF, or IPS‐1) whereas stimulation
through TLR3 activates TRIF while TLR7 and TLR9 activate MyD88. Regardless of the
route of stimulation, all sensors converge on a complex of proteins including TRAF6,
NEMO, RIP1, TAK1, IKKα, and IKKβ. NF‐κB is held inactive in the cytoplasm by
interaction with IκBα. The IKKs phosphorylate IκBα, which is then ubiquitinated and
subsequently degraded freeing NF‐κB to translocate to the nucleus (Brown, et al., 1995).
Several of the key proteins involved in NF‐κB activation are activated by
polyubiquitination, including RIG‐I, MAVS, TRIF, TRAF6, RIP1, NEMO, and NF‐κB, which is
also activated indirectly by the polyubiquitination of IκBα (Bhoj and Chen, 2009; Bibeau‐
Poirier and Servant, 2008). In fact, cellular DUBs CYLD and A20 negatively regulate the
induction of NF‐κB. CYLD and A20 deubiquitinate RIG‐I, TRAF6, and RIP1, and CYLD can
also remove Ub from NEMO (Evans, et al., 2004; Kovalenko, et al., 2003; Saitoh, et al.,
2005; Trompouki, et al., 2003; Wang, et al., 2004; Zhang, et al., 2008).
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Activation of IRF‐3
The current model for activation of IRF‐3 begins similarly to that of NF‐κB. The
PRRs bind to their respective adaptor proteins; however, a different complex of proteins
downstream of MAVS, MyD88, and TRIF is involved. STING, also known as MITA, ERIS,
and MPYS, has been shown to be necessary for the activation of IRF‐3 by known
inducers such as poly(IC) and Sendai virus (SeV) and is critical for the anti‐viral response
to herpes simplex virus 1 (HSV‐1) and vesicular stomatitis virus (VSV) in mice (Ishikawa
and Barber, 2008; Ishikawa, et al., 2009; Jin, et al., 2008; Sun, et al., 2009; Zhong, et al.,
2008). STING has been found to constitutively interact with both MAVS and IRF‐3
(Zhong, et al., 2008). Sun et al. demonstrated that STING dimerizes upon stimulation
with IFN inducers such as poly(dA:dT), poly(IC), and SeV (2009). The dimerization of
STING therefore brings IRF‐3 in close proximity to MAVS. Likewise, stimulation by IFN
activators or viral infection induces the interaction of TBK‐1 with TRAF3, TANK, and the
exocyst component Sec5, which activates TBK‐1 kinase activity and promotes the
recruitment of TBK‐1 to MAVS and STING (Chien, et al., 2006; Ishikawa and Barber,
2008; Zhong, et al., 2008). This allows for phosphorylation of both STING and IRF‐3 by
TBK‐1, which activates IRF‐3 to dimerize, translocate to the nucleus, and stimulate type I
IFN induction. The activation of IRF‐3 is negatively regulated by cellular DUBs.
Deubiquitination of RIG‐I by CYLD and A20 as well as removal of Ub from TRAF3 by
DUBA can inhibit IRF‐3 activation (Kayagaki, et al., 2007; Saitoh, et al., 2005; Wang, et
al., 2004).
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IFN ANTAGONISM BY PLPS
MHV PLP2
The necessity to evade the innate immune response and the encoding of DUB
activity suggests that the PLPs may be able to modulate the host innate immune
response adding yet another layer of complexity to the multifaceted nature of the PLPs.
Zheng et al. demonstrated that the second papain‐like protease (PLP2) of MHV is able to
inhibit IFN‐β reporter activity stimulated by MAVS, TBK‐1, and IRF‐3 overexpression.
Additionally, PLP2 and IRF‐3 were found to associate by co‐immunoprecipitation and the
ubiquitination and nuclear translocation of IRF‐3 was abrogated by co‐expression of
PLP2 (Zheng, et al., 2008). When the catalytic cysteine was mutated to alanine, which
ablates proteolytic and DUB activity, MHV PLP2 was no longer able to inhibit IFN‐β
reporter activity suggesting that enzymatic activity, presumably DUB activity, is
necessary for IFN antagonism (Zheng, et al., 2008).

SARS‐CoV PLpro
Using reporter assays, Devaraj et al. found that SeV‐induced IFN‐β promoter
driven luciferase production was potently and dose‐dependently inhibited by expression
of SARS‐CoV PLpro (2007). A similar effect was observed by a construct
of PLpro that contains the downstream hydrophobic domains that tether PLpro to
membranes (PLpro‐TM). In contrast to PLP2 of MHV, when the catalytic cysteine was
mutated to alanine, thereby abrogating any proteolytic function, PLpro‐TM was able to
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dose‐dependently inhibit SeV induced IFN‐β‐Luc albeit to a lesser extent than wildtype
(Devaraj, et al., 2007). These data suggest that catalytic activity contributes to IFN
antagonism, but is not strictly required. This conclusion is further supported by the
pharmacological inhibition of wildtype PLpro using a PLpro‐specific inhibitor GRL‐0617S
(Clementz, et al., 2010; Ratia, et al., 2008). In this experiment, cells were transfected
with luciferase reporters dependent on IRF‐3 (ISRE‐Luc), NF‐κB, (NF‐κB‐Luc), and both
IRF‐3 and NF‐κB (IFN‐β‐Luc) along with two increasing concentrations of PLpro. N‐RIG (a
dominant active form of RIG‐I) stimulation of ISRE‐Luc and IFN‐β‐Luc was significantly
and dose‐dependently reduced by PLpro in the presence or absence of GRL‐0617S
consistent with a catalytic independent mechanism of PLpro‐mediated inhibition of IRF‐
3 activity and IFN‐β induction. Intriguingly, the ability of PLpro to inhibit TNF‐α‐induced
NF‐κB‐Luc was abrogated in the presence of GRL‐0617S suggesting that catalytic activity
is required for inhibition of NF‐κB activity (Clementz, et al., 2010).
The mechanism of inhibition by PLpro was further explored in the Devaraj et al.
study and PLpro was found to inhibit SeV induced phosphorylation, dimerization, and
nuclear translocation of IRF‐3. Using co‐immunoprecipitation experiments, an
association between PLpro and IRF‐3 was reported (Devaraj, et al., 2007). Further
analysis into the interaction between PLpro and IRF‐3 has demonstrated that the
association is likely indirect. Gel shift assays using purified PLpro and IRF‐3
demonstrated that these two proteins do not directly interact in vitro (Frieman, et al.,
2009). Therefore, PLpro is inhibiting the induction of type I IFN by associating with IRF‐
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3; however, the association requires some other cellular protein(s) involved in the
signaling cascade that interact with IRF‐3.

HCoV‐NL63 PLP2
Since HCoV‐NL63 PLP2 possesses DUB activity, it too was tested for the ability to
antagonize type I IFN induction. N‐RIG‐induced stimulation of IFN‐β‐Luc was found to
be dose‐dependently inhibited by PLP2 in a similar manner to SARS‐CoV PLpro
(Clementz, et al., 2010; Frieman, et al., 2009). Like SARS‐CoV PLpro, both the soluble
and TM forms of PLP2 as well as the catalytic cysteine mutants are IFN antagonists.
Correspondingly, the catalytic cysteine mutant is less effective than wildtype (Clementz,
et al., 2010). The similarities between PLpro and PLP2 suggest that PLP2 may also
antagonize the activation of IRF‐3. In line with this prediction, PLP2 and IRF‐3 were
reported to associate by co‐immunoprecipitation and the nuclear translocation of IRF‐3
was inhibited by PLP2 (Clementz, et al., 2010). Again, the exact mechanism of inhibition
of IRF‐3 by PLP2 is unclear. Thus, another major goal of my dissertation work was to fill
in the gaps in our understanding of how the PLPs from SARS‐CoV and HCoV‐NL63
antagonize the induction of type I IFN induction.

CHAPTER II
MATERIALS AND EXPERIMENTAL METHODS

VIRUSES
MHV‐A59 icv (also referred to as WT‐A59 icv), Alb ts6 icv, and nsp4‐N176A icv
were generated using the MHV‐A59 reverse genetics system developed by Yount et al.
(2002). A plaque purified isolate of HCoV‐NL63 was kindly provided by Dr. Christian
Drosten. SeV was purchased from Charles River laboratories.

CELL LINES
Delayed brain tumor (DBT) and baby hamster kidney (BHK) expressing the MHV
receptor (BHK‐MHVr) cells were incubated at 37°C in minimal essential medium, MEM,
(Gibco) containing 5% fetal calf serum (FCS), 10% tryptose phosphate broth, 2%
penicillin/streptomycin, and 2% L‐glutamine. HeLa‐MHVr and HEK293 cells were
propagated in DMEM (Gibco) containing 10% FCS, 0.001 M sodium N‐2‐
hydroxyethylpiperazine‐N’‐2‐ethanesulfonic acid, pH 7.4, 1% penicillin/streptomycin and
1% L‐glutamine.
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BACTERIA STRAINS
The various strains used to propagate plasmid DNA are listed in Table 1. All
strains were cultured in Luria‐Bertani (LB) broth or on LB + bactoagar plates. Ampicillin
(AMP) resistant clones were propagated in 100 μg/mL AMP. Kanamycin (KAN) resistant
clones were grown in 50 μg/mL KAN. Standard microbiological methods were used to
culture bacterial strains (Sambrook, et al., 1989)

PLASMID DNA
Clones A‐G encoding fragments of the MHV genome were provided by Dr. Ralph
Baric (University of North Carolina) and described by Yount et al. (2002). pcDNA3.1‐
Flag‐Ub was kindly provided by Dr. Adriano Marchese (Loyola University Medical
Center). IFN‐β‐Luc was kindly provided by Dr. John Hiscott (Jewish General Hospital,
Montreal, Canada). pISRE‐Luc has been previously described (Li, et al., 2005a). pRL‐TK
renilla luciferase reporter was purchased from Promega. N‐RIG‐Flag, NF‐κB‐Luc, and
nsp2/3‐GFP were kindly provided by Dr. Ralph Baric. pcDNA3‐Myc6‐mISG15 was kindly
provided by Dr. Min‐Jung Kim (Pohang University of Science and Technology, Pohang,
Republic of Korea). pcDNA3‐Ube1L and pcDNA3‐UbcH8 were kind gifts from Robert M.
Krug (University of Texas). Human STING‐HA was given by Dr. Glen Barber (University of
Miami) and mouse STING‐HA and STING‐FLAG were obtained from Zhongbin Chen
(Beijing Institute of Radiation Medicine).
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To obtain high expression in eukaryote cells, the codon usage of HCoV‐NL63
PLP1 core domain (amino acid 1018‐1277 of HCoV‐NL63) and PLP2 core domain (amino
acid 1570‐1884) were optimized based on human codon usage frequency, and the
potential splicing sites and poly(A) signal sequences were removed and cloned into
pcDNA3.1‐V5/HisB at BamHI and EcoRI sites as an in‐frame fusion with the V5 peptide.
The native viral sequence for the remainder of nsp3 (including the transmembrane
domains downstream of PLP2) was cloned into pcDNA3.1‐PLP2(N) using the existing
EcoRI site and XhoI to generate PLP2‐TM in frame with the V5 peptide using primers
listed in Table 2.

SITE‐DIRECTED MUTAGENESIS
To engineer specific mutations into plasmid DNA, the QuikChange II XL Site‐
Directed Mutagenesis Kit was used. Briefly, high performance liquid chromatography
purified primers were obtained from IDT‐DNA technologies. These primers contain two
nucleotide substitutions to engineer non‐synonymous amino acid mutations and are
listed in Table 2. The primers along with plasmid DNA, pfu Turbo polymerase, dNTPs,
reaction buffer, and water were mixed together and subjected to the recommended
PCR conditions. Following amplification, the parental DNA was digested by DpnI
treatment and the mutagenized plasmid DNA was transformed into chemically
competent E. coli for plasmid propagation.
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MHV REVERSE GENETICS
Plasmid Propagation
The MHV reverse genetics system contains seven clones (A‐G) that contain
fragments of varying size containing the whole of the MHV genome (Table 3). WT and
mutagenized clone B plasmids were transformed into chemically competent MDS cells
(Scarab Genomics). The remaining clones were transformed into chemically competent
XL‐1 blue cells. Competent cells were heat shocked for 45 seconds at 42°C and plated
on LB plates containing appropriate selection antibiotics. Single colonies were picked
and grown in selection media (5 mL LB + antibiotic) with shaking overnight at 25°C.
Overnight cultures were used to inoculate 400 mL of LB + antibiotic and incubated with
shaking at 25°C. Large‐scale cultures were grown until an optical density of at least 1.0
but no more than 1.5 at 590 nm. Plasmid DNA was isolated using the
PureYield Maxiprep kit (Promega) per manufacturer’s protocol or by ammonium acetate
precipitation.

Ammonium Acetate Precipitation
The protocol and reagent formulas are originally described in Saporito‐Irwin et
al. (1997). Large‐scale cultures of bacteria harboring the plasmid DNA to be isolated
were grown according to normal microbiological methods and pelleted by
centrifugation at 3,500 RPM for 10 minutes. Bacterial pellets were resuspended using
resuspension buffer, lysed in cell lysis buffer by inversion, and neutralized by inversion.
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Cell debris was separated by centrifugation at 10,000 RPM for 10 min. Sixty percent of
the recovered supernatant worth of cold isopropanol was added to the supernatant and
incubated at 4°C for 10 minutes. DNA was then pelleted by centrifugation at 10,000
RPM for 10 minutes. The pellet was resuspended in 2.0 M ammonium acetate,
incubated on ice for 10 minutes, and again centrifuged. The pellet was washed with
isopropanol, centrifuged, and incubated with 7.5 M ammonium acetate. DNA was yet
again pelleted, washed with isopropanol, pelleted, and finally resuspended in nuclease‐
free water.

Restriction Digestion and Purification of MHV Infectious Clone (ic) Fragments
The fragment coordinates, plasmid details, enzymes, and products liberated for
each clone are listed in Table 3. Four digestion reactions of 40 μg each were run for all
seven clones. Following digestion, the entire reaction mixture was run on 0.8% low‐
melt agarose (SeaPlaque GTG, FMC BioProducts). The appropriate restriction fragment
for each digestion reaction was excised from the gel and isolated using the SV Gel and
PCR CleanUp kit (Promega) per manufacturer’s protocol. The purified fragments from
the four digestion reactions were combined for each clone and subjected to chloroform
extraction by adding one‐half the volume of DNA of chloroform and vortexing for one
minute. Following centrifugation at 14,000g for five minutes, the aqueous phase
containing the DNA was carefully removed.
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Determining the Molar Ratios and Ligation of the MHV ic Fragments
Given that the fragments are of different sizes, the rough molar ratios for ligation
are determined. In these calculations, the concentration of the purified fragment (f) is
first divided by the length of the fragment to get a value termed L (L = fconc / flength). The
average of L is then determined. The amount to ligate is determined by dividing the
average of L (Lavg) by L and multiplying by 20. The calculated amounts of each fragment
are mixed together along with 1X ligase buffer and T4 DNA ligase. The ligation reactions
are incubated at 16°C for at least 24 hours.

Chloroform Extraction and Isopropanol Precipitation of MHV ic Ligation
Following ligation, 100 μL of nuclease‐free water was added to the ligation
mixture for a total of 300 μL. Then, 250 μL of chloroform was added, and the mixture
was vortexed for one minute. Following centrifugation at 14,000g for five minutes, the
aqueous phase containing the DNA was removed. 3M sodium acetate (NaOAC) at one‐
tenth the volume of extracted aqueous phase and twice the volume of isopropanol were
added in addition to 1 μL of glycogen. The reaction mixture was vortexed, incubated at
room temperature (RT) for 10 minutes, and centrifuged at 14,000g for 10 minutes. The
supernatant was discarded and the DNA pellet was washed with 1 mL of 95% ethanol
(EtOH). The DNA was again pelleted by centrifugation at 14,000g for 10 minutes. The
supernatant was discarded and the pellet was allowed to dry for 15‐30 minutes. When
all the EtOH evaporated, the pellet was resuspended in 11 μL of nuclease‐free water.
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Purified ligation products (3 μL) were run on 0.8% agarose gel to visualize the major
ligation products and their sizes.

In Vitro Transcription of MHV ic cDNA to Generate MHV ic RNA
MHV ic and N gene RNA were generated by in vitro transcription of MHV ic cDNA
and linearized N‐gene plasmid DNA respectively using the mMessage mMachine T7 kit
(Ambion) according to the manufacturer’s instructions. To synthesize MHV ic RNA, 7.5
μL of purified MHV ic cDNA was added to 7.5 μL of 30 mM GTP, 2.5 μL 2X NTP/CAP, 5 μL
10X reaction buffer, and 5 μL enzyme mix for a total of 50 μL. N gene RNA was
synthesized similarly with the following exceptions: half of each reagent was used for a
total of 25 μL per reaction, AdeI linearized N gene DNA was the template, and water was
substituted for the GTP reagent. Both reactions were incubated at 37°C for three hours.

Electroporation of MHV ic and N gene RNA into BHK‐MHVr Cells
DBT and BHK‐MHVr cells, seeded in a T75 flask, were washed with 10 mL of
phosphate buffered saline (PBS) and incubated with 1X trypsin to detach the cells. For
DBT cells, 1.5 X 106 cells were plated per 60 mm dish (two per virus) and incubated at
37°C while the BHK‐MHVr cells were prepared for electroporation. The trypsinized BHK‐
MHVr cells were washed three times with cold PBS and resuspended in PBS to a
concentration of 1 X 106 cells per mL. 800 μL of BHK‐MHVr cells were added to a 0.4 cm
gap electroporation cuvette (BioRad). The MHV ic and N gene RNA was added to the
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cuvette and electroporated into the BHK‐MHVr cells using the BioRad Gene Pulser at 25
μF and 800 volts using two pulses. Following electroporation, the cuvettes were
incubated on ice for 10 minutes. Half of the volume in the cuvette was added to each of
two 60 mm dishes seeded with DBT cells and incubated at 33°C for 24 to 48 hours and
scored for CPE.

Isolation and Verification of MHV ic Virus
If CPE was observed, supernatants were collected and used to infect a fresh
monolayer of DBT cells to further propagate the virus. Concurrently, RNA was isolated
from the infected cells using the RNeasy Kit (Qiagen) per manufacturer’s instruction.
The region of viral RNA containing the mutation of interest was RT‐PCR amplified using
the ImProm‐II RT System (Promega) followed by the Advantage cDNA PCR kit
(Clonetech) according to manufacturer’s instructions. Specific primers are listed in
Table 2. The PCR products were sequenced to verify MHV infection as well as to confirm
the presence of engineered mutations in MHV ic mutants.

PLAQUE ASSAY
Two sets of DBT cells, plated in 60 mm dishes, were infected with WT‐A59 icv,
Alb ts6 icv, or nsp4‐N176A icv at an MOI of 0.1. One set of infected cells was maintained
at the permissive temperature of 33°C, while the other was incubated at the non‐
permissive temperature of 39.5°C. At 15 hours post infection (hpi), cell‐free
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supernatant was collected. Ten‐fold serial dilutions (in triplicate) of isolated
supernatant were used to infect DBT cells seeded to 70% confluency in 12 well plates.
Following a 1 hour absorption period, a 1 ml mixture of 0.4% Noble agar (DIFCO) and
MEM with 1% FCS and 2% penicillin/streptomycin was added to each well. Infection
was maintained for 48 hours at the permissive temperature (33°C) and plates were
stained with 0.1% crystal violet solution for 10 minutes at room temperature to visualize
and count plaques.

TEM ANALYSIS OF DMVs
Two sets of DBT cells were infected with WT‐A59 icv or Alb ts6 icv at an MOI of
1.0 and incubated at 33°C. At 3.5 hpi, one set of infected cells was shifted to 39.5°C. At
5.5 hpi, cells were harvested and processed for TEM analysis as previously described
(Gosert, et al., 2002)

CONFOCAL MICROSCOPY
Analysis of MHV Replicase Protein Localization
Two sets of DBT or HeLa‐MHVr cells were grown to semi‐confluence in 8 well
chamber slides coated with permanox. Cells were infected with WT‐A59 icv or Alb ts6
icv at an MOI of 1.0 and incubated at 33°C for a 1 hour absorption period. At 3.5 hpi,
one set of infected cells was shifted to 39.5°C. At 5 hpi, cells were labeled with 65 nM
MitoTracker Red fluorescent dye (Invitrogen). At 5.5 hpi, cells were washed 3 times
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with PBS and fixed for 30 min at room temperature with 3.7% formaldehyde in PBS.
Cells were then permeabilized for 10 min at room temperature with 0.1% Triton X‐100
in PBS. Following permeabilization, cells were incubated with either α‐nsp3 or α‐nsp4
and/or α‐PDH antibodies overnight at 4°C. Cells were then washed 3 times for 30
minutes in PBS. After washing, cells were incubated with AlexaFluor 488 conjugated
chicken α‐rabbit IgG (Invitrogen) and/or AlexaFluor 568 goat α‐mouse IgG (Invitrogen)
secondary antibody for 30 minutes at room temperature. Cells were again washed 3
times for 30 minutes in PBS. Cells were imaged on the Zeiss 510 confocal microscope.

Localization of nsp4‐GFP and nsp4‐N258T‐GFP
To determine if the ts lesion affects mature nsp4 in the absence of MHV
infection, wildtype and mutant nsp4 proteins were expressed in BHK‐T7 cells plated on 8
well permanox treated chamber slides and incubated at either the permissive and non‐
permissive temperature. At 24 hours post transfection, cells were labeled with anti‐PDI
and AlexaFluor 568 to detect ER or MitoTracker to detect mitochondria shown in red.
The GFP fused to the construct is autofluorescent and is green. Cells were imaged on
the Zeiss 510 confocal microscope.

Determination of IRF‐3 Localization
HEK293 cells were plated on fibronectin (12 μL of fibronectin (Sigma) per mL of
PBS) treated glass cover slips and transfected with 225 ng STING‐HA in the presence or
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absence of 300 ng of PLP2‐TM using LT‐1 transfection reagent (MirusBio). At 16 hours
post transfection, cells were fixed with 3.7% formaldehyde for 10 min at room
temperature. Cells were then incubated with 1:200 dilution of rabbit anti‐IRF‐3 (Active
Motif), mouse anti‐HA (Covance), and goat anti‐V5 (Genscript) in ADPS (PBS + 0.1%
Triton‐X100 + 5% fetal calf serum) for 1 hour at room temperature. Cells were washed
3X with PBS and incubated with 1:200 dilution of chicken anti‐rabbit AlexaFluor (AF)
488, donkey anti‐mouse AF568, and donkey anti‐goat AF647 (Molecular Probes) in
ADPS for 1 hour in the dark. Cells were again washed 3X with PBS, mounted, and
imaged with the Zeiss LSM‐510 confocal microscope.

WESTERN BLOT ANALYSIS
Cell lysates were prepared in 2X lysis buffer A (4% SDS, 3% DTT, 40% glycerol and
0.065 M Tris pH 6.8), ELB (0.5% Triton‐X‐100, 150 mM NaCl, 12.5mM β‐
glycerolphosphate, 1.5 mM MgCl2, 2 mM EGTA, 10 mM NaF, 1 mM Na3VO4, 2 mM DTT
plus protease inhibitor cocktail (Roche)) or TLB (1.0% Triton‐X‐100, 150 mM NaCl, 2 mM
EDTA, and protease inhibitor cocktail). Samples lysed with ELB or TLB were then mixed
1:1 with 2X sample buffer. Proteins were separated via SDS‐PAGE, followed by transfer
to nitrocellulose membrane in transfer buffer (0.025 M Tris; 0.192 M glycine, and 20%
methanol) for 2 hours (55 volts) at 4°C. The membrane was blocked using 5% dried skim
milk in Tris‐buffered saline (TBS) (0.9% NaCl; 10 mM Tris‐HCl, pH 7.5) plus 0.1% Tween
20 (TBST) overnight at 4°C. The blot was probed with the primary antibody for 1 hour at
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room temperature. The membrane was washed in TBST three times for 20 minutes for
each wash. Following the washes, the membrane was incubated with peroxidase‐
conjugated secondary antibodies (donkey anti‐rabbit or goat anti‐mouse IgG HRP)
(Amersham) at a dilution of 1:10,000 for 1 hour at room temperature. The membrane
was then washed three times with TBST and detected with the Western Lightning
Chemoluminescence Reagent Plus (PerkinElmer LAS Inc.).

DUAL LUCIFERASE REPORTER ASSAY
To determine the effect of PLPs on the induction of type I IFN induction, the IFN‐
β‐Luc reporter consisting of the IFN‐β promoter upstream of firefly luciferase was
transfected into HEK293 cells along with the various PLP constructs and catalytic
mutants. pRL‐TK encoding renilla luciferase under the control of the herpes simplex
thymidine kinase promoter (low to moderate renilla expression) was used for
normalization of transfection efficiency. N‐RIG‐Flag, a dominant active portion of RIG‐I
was co‐transfected to activate the IFN induction pathway. DNA was delivered into
HEK293 cells by LT‐1 Transfection Reagent (MirusBio) according to manufacturer’s
instruction and incubated at 37°C for 24 hours.
Firefly luciferase and renilla luciferase activities were assayed using the dual
luciferase reporter assay Kit (Promega). Briefly, cells were lysed using 1X passive lysis
buffer. Then, 25 μL of the lysate was added to a white luminometer plate. Each well
was injected with 100 μL of LARII reagent and firefly luciferase activity was measured.
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Then each well was injected with 100 μL of Stop‐and‐Glo reagent, which quenches
firefly luciferase luminescence and simultaneously activates renilla luciferase
luminescence. The light generated by each luciferase catalyzed reaction is quantitated
by a luminometer.
To determine the effect of PLP2‐TM on STING stimulated cells, HEK293 cells
were transfected with MirusBio LT1 transfection reagent per manufacturer’s
instructions. HEK293 cells, seeded in 24 well plates, were transfected with 50 ng of
pISRE‐luciferase and 25 ng of pRL‐TK. Cells were stimulated by transfection of 225 ng of
STING‐HA and the antagonism of STING‐induced ISRE‐Luc was assessed at 75, 150, and
300 ng of PLP2‐TM or the corresponding catalytic cysteine mutant C1678A. At 20 hours
post transfection, cells were lysed in 1X passive lysis buffer (Promega) and assayed for
luciferase production via the dual luciferase reporter assay (Promega) per
manufacturer’s instruction and a luminometer. Cell lysates were mixed 1:1 with 2X
Laemmli Buffer (4% SDS, 20% glycerol, 10% 2‐mercaptoethanol, 0.125 M Tris HCl, and
0.004% bromphenol blue (pH 6.8)) and run on 10% SDS‐PAGE, transferred to
nitrocellulose, and blotted for expression of STING‐HA using mouse anti‐HA (Covance)
and PLP2‐TM‐V5 with mouse anti‐V5 (Invitrogen).
To determine the effect of pharmacological inhibition of PLpro on IFN
antagonism, HEK293 cells were transfected with plasmids encoding PLpro‐TM (Devaraj,
et al., 2007), IFN‐β‐Luc, ISRE‐Luc, NF‐κB‐Luc, pRL‐TK, nsp2/3‐GFP substrate, and/or N‐
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RIG‐Flag. The pcDNA3.1/V5‐HisB vector was used to standardize DNA concentration for
transfection. DMSO vehicle control or 100 μM of GRL‐0617S (Ratia, et al., 2008) was
added at the time of transfection. TNF‐α (10 ng/mL) from Roche was used to stimulate
the NF‐κB‐Luc reporter (6 hour stimulation). Cell lysates were prepared per
manufacturer’s instruction using 1X passive lysis buffer (Promega), and luciferase
activity was measured using the dual luciferase reporter assay kit (Promega) and a
luminometer. Cell lysates were also mixed 1:1 with 2X Laemmli Buffer and subjected to
western blot as described above. PLpro‐TM was detected with anti‐V5 (Invitrogen), and
nsp2/3‐GFP and nsp3‐GFP were detected with rabbit anti‐GFP (Invitrogen).

TRANS‐CLEAVAGE ASSAY
To demonstrate either catalytic activity of the mutants or the efficacy of the
PLpro‐specific inhibitor GRL‐0617S, a trans‐cleavage assay was performed. HEK293 cells
were transfected with the protease and an nsp2/3‐GFP construct. The nsp2/3‐GFP
substrate contains the junction, including the cleavage site, between nsp2 and nsp3,
which is normally cleaved by the papain‐like protease in the context of viral infection.
This construct, when expressed, generates a protein that is approximately 35 kDa.
Cleavage of this protein liberates nsp2 and nsp3‐GFP with the latter being detectable
upon western blot with anti‐GFP as a 20 kDa protein.
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PROTEIN PULL‐DOWN ASSAY
Co‐immunoprecipitation
HEK293 cells were transfected with epitope tagged proteins and incubated at
37°C for 24 hours. Following transfection, cells were washed with PBS then lysed in TLB
or ELB. Cell lysates were centrifuged at 14,000g for 15 minutes at 4°C. The
supernatants were collected and 150 μL of lysate was precleared by incubation with 10
μL of either PureProteome protein A or G magnetic beads (Millipore). The precleared
lysate was incubated with 2 μg of immunoprecipitating antibody at 4°C for 6 hours.
Then, 25 μL of protein A or G magnetic beads was added and incubated at 4°C
overnight. The beads were then immobilized using a magnetic rack and washed a
minimum of three times with cold TLB or ELB. Following the washes, proteins were
eluted by addition of 1X Laemmli Buffer and incubation at 37°C for 30 minutes. Proteins
were separated by SDS‐PAGE and detected via western blot.

HaloTag Pull‐down Assay
The HaloTag is a hydrolase derivative that makes non‐reversible covalent
attachment to a number of known ligands (Promega). This polypeptide can be fused to
proteins of interest allowing a wide variety of assays to be performed on the tagged
fusion protein such as immunofluorescence, western blot, protein purification, and
protein‐protein interaction assays. PLpro was cloned into the HaloTag vector with the
tag at the C‐terminus of PLpro. PLpro‐HALO was transfected into HEK293 cells using
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MirusBio LT‐1 transfection reagent and incubated at 37°C for 24 hours. Following
transfection, cells were washed with PBS then lysed in TLB. Cell lysates were
centrifuged at 14,000g for 15 minutes at 4°C. The supernatants were collected and 150
μL of lysate was incubated with 30 μL of HaloMAG magnetic beads (Promega) at 4°C
overnight. The beads were then immobilized using a magnetic rack and washed a
minimum of three times with cold TLB. Following the washes, proteins were eluted by
addition of 1X Laemmli Buffer and incubation at 90°C for 10 minutes. Proteins were
separated by SDS‐PAGE visualized by silver stain.

SILVER STAIN AND MASS SPECTROMETRY ANALYSIS OF PLpro INTERACTING PROTEINS
Samples were prepared and processed as described in the HaloTag Pull‐down
Assay section. Following separation by SDS‐PAGE, the gel was silver stained to visualize
proteins using the Silver Stain Plus kit (BioRad) per manufacturer’s instructions. Gel
slices were cut corresponding to regions of differences between vector and PLP
transfected cell lysates. The gel slices were destained using a 30 mM potassium
ferricynide and 100 mM sodium thiosulfate solution until the brown color disappeared
and the gel slice was clear. The destaining solution was removed and the gel slice was
washed for 10 minutes 5 times with water. The sample was stored in water and sent to
University of Arizona Proteomics Consortium for mass spectrometry analysis. Results
were analyzed using the Scaffold 2 proteome software.

CHAPTER III
EXPERIMENTAL RESULTS

GLYCOSYLATION OF nsp4
nsp4 contains two asparagines that fit a consensus sequence (NxS) for N‐linked
glycosylation. The first is asparagine at amino acid number 176 (where amino acid 1 is
the first residue in nsp4), and the second is asparagine 237. First, to demonstrate that
nsp4 is glycosylated in MHV infection, cells were infected with MHV‐A59 and were
treated with either tunicamycin (inhibits N‐linked glycosylation) or lysates harvested
from MHV infected cells were treated with endoglycosidase H (cleaves N‐linked glycans)
and subjected to immunoprecipitation with an antibody that binds to the p150
precursor as well as nsp4. A faster migrating species for both p150 and nsp4 was
detected in tunicamycin or endoH treated samples compared with untreated lysates
suggesting that both p150 and mature nsp4 are glycosylated in MHV infected cells
(Clementz, et al., 2008). To confirm that N176 and N237 are the asparagines that
become glycosylated, site‐directed mutagenesis was performed on constructs encoding
nsp4. N176 and/or N237 were changed to alanine thereby abrogating the ability for N‐
linked glycosylation at these two residues. The mobility of wildtype, N176A, N237A, and
N176A/N237A in lysates treated or untreated with endoH was assessed. Each single
47
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mutant migrated equivalently and faster than wildtype nsp4 and the double mutant
migrated faster than either single mutant. All endoH treated constructs migrated
equivalently to the N176A/N237A double mutant (Clementz, et al., 2008). These data
collectively suggest that nsp4 is glycosylated and that glycosylation takes place at N176A
and N237A.

GENERATION OF MHV ic MUTANT VIRUSES
To characterize the importance of glycosylation of these sites in MHV infection,
two nucleotide substitutions to generate asparagine to alanine mutations were
engineered in the B clone of the MHV reverse genetics system using site‐directed
mutagenesis. The mutated plasmids were transformed into and propagated in MDS
cells. Following large‐scale DNA isolation, the plasmids were sequenced to verify the
two nucleotide replacement. The seven MHV ic clones and the mutant clone B plasmids
were restriction digested as outlined in Table 3. The MHV ic fragments were extracted
from 0.8% low melt gel and further purified by chloroform extraction. The isolated and
purified fragments are displayed in Figure 7. Since the fragments are of varying sizes, a
calculation of molar ratios for ligation was performed as described in the methods
section. The calculated amounts of all seven fragments were mixed together and
ligated at 16°C. The ligation products before purification are shown in Figure 8. The
ligation products were then chloroform extracted and purified by alcohol precipitation
(Figure 8). The purified MHV ic cDNA and N gene were in vitro transcribed into RNA that
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Figure 7. MHV ic fragments. (A) Schematic diagram of the MHV genome and the
restriction enzymes that liberate the fragments from clones A‐G that span the
genome (modified from Yount et al., 2002). (B) Clones A‐G for wildtype MHV ic (left)
and clone B mutant plasmids (right) were digested, isolated by gel purification, and
chloroform extracted. To demonstrate purity and correct fragment size, 1 μL of each
fragment was run on 0.8% agarose gel, stained with ethidium bromide, and visualized
by the AlphaImager 2000.
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Figure 8. MHV ic ligation products. 5 μL of the ligation reaction before purification
(Raw) and 3 μL of the purified ligation reaction were run on a 0.8% agarose gel,
stained with ethidium bromide, and visualized by the AlphaImager 2000.
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was then electroporated into BHK‐MHVr cells. As seen in Figure 9, expression of the
MHV ic RNA results in the production of progeny virus that induce CPE. Since the
expression of spike alone can induce cell‐cell fusion and syncytia formation, which is
indistinguishable from that induced by viral infection, the supernatants were collected
and passaged twice to both verify and amplify infectious virus.
Sawicki et al. proposed that another asparagine residue within the luminal
region of nsp4 confers a temperature sensitive phenotype; however, the chemically
mutagenized isolate (termed Alb ts6) contained other mutations throughout the
genome such that the authors could not definitively conclude that the N258 to
threonine mutation is causative (2005). If this mutation is responsible for the ts lesion,
then the loss of function of nsp4 at the non‐permissive temperature could be studied to
further understand the function of nsp4 in MHV replication. Thus, the N258T mutation
was reverse engineered into otherwise wildtype MHV and assessed for temperature
sensitivity (Figures 7‐9).

VERIFICATION AND CHARACTERIZATION OF MHV ic MUTANT VIRUSES
After amplification and generation of stocks of MHV ic viruses, a fresh monolayer
of DBT cells was infected with the MHV ic viruses and total RNA was isolated. The RNA
was reverse transcribed into cDNA and the region of mutation was PCR amplified. The
amplicons were sequenced to verify the presence of the engineered mutations. As seen
in Figure 10, the two nucleotide substitutions in the N176A and N258T mutants are
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Figure 9. Cytopathic effect (syncytia) formation induced by MHV icv. BHK‐MHVr cells
were electroporated with or without MHV ic RNA for WT‐A59, N176A (A), and N258T
(B) and layed over a monolayer of DBT cells. Cells were incubated at 33°C until CPE
was observed (approximately 40‐48 hours post electroporation). Mock represents
BHK‐MHVr cells electroporated in the absence of MHV ic RNA and layed over a
monolayer of DBTs.
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Figure 10. Sequence analysis of mutant infectious clone virus. DBT cells were
infected with WT‐A59 icv, nsp4‐N176A icv (A), or Alb ts6 icv (B) and at 12 hpi RNA
was isolated. RT‐PCR was performed on viral RNA using primers listed in Table 2, and
PCR products were sequenced across the nsp4 region.
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present in the mutant MHV ic. The N237A mutant and the N176A/N237A double
mutant were unable to be recovered suggesting that glycosylation of N237 is important
for MHV replication.
To determine if either the N176A or N258T ic virus (referred to as nsp4‐N176A
icv and Alb ts6 icv respectively) are temperature sensitive, the amount of infectious
particles produced by virus infected cells was measured by incubating virally infected
DBT cells at the permissive (33°C) or non‐permissive (39.5°C) temperature and titrating
at the permissive temperature. Two sets of DBT cells were infected with WT‐A59 icv,
Alb ts6 icv, or nsp4‐N176A icv at an MOI of 0.1. One set of infected cells was maintained
at the permissive temperature of 33°C, while the other was incubated at the non‐
permissive temperature of 39.5°C. At 15 hpi, cell‐free supernatant was collected. Ten‐
fold serial dilutions (in triplicate) of isolated supernatant were used to infect DBT cells
incubated at the permissive temperature. After 48 hours, plaques were counted and
viral titer was determined. WT‐A59 icv replicated to high titers of 1.08x107 plaque
forming units (PFU)/ml at 33°C and 1.42x107 PFU/ml at 39.5°C. nsp4‐N176A icv also
produced similar size plaques and reached titers of 1.33x107 PFU/ml at 33°C and
1.75x107 PFU/ml at 39.5°C. The Alb ts6 icv replicated efficiently at 33°C (1.08x107
PFU/ml), but replication was dramatically reduced at 39.5°C (4.08x102 PFU/ml) (Figure
11). One‐step growth curve analysis then was performed on WT‐A59 icv, Alb ts6 icv,
and nsp4‐N176A icv. DBT cells were infected with icv at a MOI of 0.1, incubated at the
permissive temperature, and production of infectious virus was monitored periodically
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Figure 11. Growth characteristics of infectious clone viruses. Titer of WT‐A59 icv, Alb
ts6 icv, and nsp4‐N176A icv following infection at the permissive and non‐permissive
temperature and titrated at 33°C. Plaques were counted 48 hours post infection.
Black bars, WT‐A59 icv; White bars, Alb ts6 icv; Gray bars, nsp4‐N176A icv.
Performed in triplicate; error bars indicate standard deviation from the mean.
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over the course of 24 hours by plaque assay. When grown at 33°C, WT‐A59 icv, Alb ts6
icv, and nsp4‐N176A icv all replicated with indistinguishable kinetics, but a statistically
significant defect in growth was observed in the Alb ts6 icv upon incubation at the non‐
permissive temperature using a temperature shift growth curve analysis (Clementz, et
al., 2008).
Given the hypothesized role of nsp4 in membrane rearrangements, DMV
formation in WT‐A59 icv and Alb ts6 icv was assessed by TEM analysis. Two sets of DBT
cells were infected with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and incubated at
33°C. At 3.5 hpi, one set of infected cells was shifted to 39.5°C. At 5.5 hpi, cells were
harvested and processed for TEM analysis. DMVs can be visualized by TEM as darkly
ringed vesicles in the cytoplasm of MHV infected cells (Gosert, et al., 2002). As shown in
Figure 12, DMV formation induced by WT‐A59 icv was similar at both the permissive and
non‐permissive temperature. At 33°C, the Alb ts6 icv induced DMV formation
comparable to WT‐A59 icv; however, at the non‐permissive temperature of 39.5°C, the
Alb ts6 icv produced fewer DMVs. Intriguingly, the morphology of the mitochondria
appeared to be altered in cells infected with the Alb ts6 icv incubated at 39.5°C. As seen
in Figure 12D, the mitochondria were larger and extensively vacuolated.
The overall reduction in DMVs and the striking change in mitochondrial
morphology led to the hypothesis that the mutation in nsp4 resulted in altered
localization of nsp4 and potentially other MHV replicase products. To test this
hypothesis, the localization of nsp4 and nsp3 were assessed in MHV ic infected cells.
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Figure 12. TEM analysis of DMV formation by the WT‐A59 icv and Alb ts6 icv at the
permissive and non‐permissive temperatures. Two sets of DBT cells were infected
with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and incubated at 33°C (A and C). At
3.5 hpi, one set of infected cells (B and D) was shifted to 39.5°C. At 5.5 hpi, cells
were harvested and processed for TEM analysis. DMVs can be visualized by TEM as
darkly ringed vesicles in the cytoplasm of MHV infected cells indicated by the arrows.
Asterisks denote mitochondria. Scale bar equals 1 micron.
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Two sets of DBT cells were infected with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and
incubated at 33°C. At 3.5 hpi, one set of infected cells was shifted to 39.5°C. At 5 hpi,
cells were labeled with MitoTracker Red fluorescent dye, which is concentrated by
actively respiring mitochondria. A half an hour later, cells were harvested, fixed, and
permeabilized for immunofluorescence assays. Permeabilized cells were then incubated
with antibodies to either nsp3 or nsp4. As shown in Figure 13, staining for nsp4 (green)
and mitochondria (red) was non‐overlapping in cells infected with WT‐A59 icv at either
temperature. At the permissive temperature, Alb ts6 icv nsp4 and mitochondria
displayed a very slight increase in co‐localization versus WT‐A59 icv. At 39.5°C however,
co‐localization of nsp4 and mitochondria was substantially increased. The intensity of
the red signal was also increased in cells infected with Alb ts6 icv at the non‐permissive
temperature, which may reflect the increase in size of the mitochondria that was
observed by TEM. Similar results were obtained in three independent experiments,
with extensive co‐localization detected only in the Alb ts6 icv infected cells incubated at
the non‐permissive temperature.
To extend these findings, similar experiments were performed using HeLa cells
stably transfected with the MHV receptor (MHVr) (Figure 14). Two sets of HeLa‐MHVr
cells were infected with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and incubated at
33°C. At 3.5 hpi, one set of infected cells was shifted to 39.5°C. At 5 hpi, mitochondria
were labeled with MitoTracker Red fluorescent dye or following fixation with an
antibody to pyruvate dehydrogenase (PDH), which is a mitochondrial matrix protein.
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Figure 13. Localization of MHV replicase proteins and a mitochondrial marker in DBT
cells infected with WT‐A59 icv and Alb ts6 icv. Two sets of DBT cells were infected
with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and incubated at 33°C. At 3.5 hpi, one
set of infected cells was shifted to 39.5°C. At 5 hpi, cells were labeled with
MitoTracker Red fluorescent dye. At 5.5 hpi, cells were harvested, fixed, and
permeabilized for immunofluorescence assays. Permeabilized cells were then
incubated with antibodies to either nsp4 (A) or nsp3 (B). Scale bar equals 10
microns.
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Figure 14. MHV replicase protein localization in icv infected HeLa‐MHVr cells using
antibodies to the mitochondrial protein pyruvate dehydrogenase (PDH). Two sets of
HeLa‐MHVR cells were infected with WT‐A59 icv or Alb ts6 icv at an MOI of 1.0 and
incubated at 33°C. At 3.5 hpi, one set of infected cells was shifted to 39.5°C. At 5.5
hpi, cells were harvested, fixed, and permeabilized for immunofluorescence assays.
Permeabilized cells were then incubated with antibodies to PDH and either nsp4 (A)
or nsp3 (B). Scale bar equals 10 microns.
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Antibodies against nsp3 and nsp4 were again used to detect replicase products. As seen
in Figure 14, extensive overlap between replicase proteins nsp3 and nsp4 and
mitochondria was detected only in the Alb ts6 icv infected cells incubated at the non‐
permissive temperature (39.5°C). Similar results were obtained with MitoTracker
stained HeLa‐MHVr cells and MitoTracker and PDH were found to completely overlap.
These results are consistent with the TEM studies and reveal that the mutant form of
nsp4 is partially localized to the mitochondria at the non‐permissive temperature.
Furthermore, co‐localization with mitochondria was also detected using the α‐nsp3
antibody in Alb ts6 icv infected cells incubated at 39.5°C (Figure 14). Thus, nsp3 and
perhaps other replicase products are misdirected due to nsp4 mis‐localization.

nsp4 OR p150
Since the nsp4 is contained within and liberated from p150, the antisera to nsp4
also detects the p150 precursor. Therefore, the ts lesion could potentially be affecting
p150 as well as nsp4. The p150 precursor is believed to be more than simply an
unprocessed intermediate protein. Experimental evidence suggests that p150 may
represent a functional cistron. Sawicki et al. found that negative‐strand synthesis is
inhibited shortly after inhibition of translation, but positive‐strand synthesis continues
unabated for one hour then declines slowly for another three hours following
cycloheximide treatment (1986a). These findings parallel those of alphaviruses, where
replicase aging (unprocessed intermediates make (‐)RNA and mature replicase makes
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(+)RNA) has been established (Sawicki and Sawicki, 1986b; Sawicki and Sawicki, 1986c).
Furthermore, ts mutants in different mature nsps within the p150 region fail to
complement, suggesting that functional p150 is needed in MHV replication (Sawicki, et
al., 2005).
To determine if mature nsp4 alone is affected by the ts lesion, complementation
analysis was performed. In these experiments, two sets of DBT cells were transfected
with vector, nsp4‐GFP, or nsp4‐N258T‐GFP for 16 hours then infected with WT‐A59 icv
or Alb ts6 icv for 24 hours. One set was incubated at the permissive temperature and
the other at the non‐permissive temperature. Supernatants were collected and titrated
on DBT cells incubated at the permissive temperature. As seen in Figure 15, virtually no
difference in viral output was detected in cells expressing either nsp4‐GFP or nsp4‐
N258T‐GFP compared with vector for either WT‐A59 icv or Alb ts6 icv at either
temperature. These data suggest that expression of wildtype nsp4 cannot complement
the defect in Alb ts6 icv infected cells incubated at the non‐permissive temperature.
The nsp4‐GFP construct was demonstrated to be recruited to replicase complexes
suggesting that transfected nsp4 is functional (Oostra, et al., 2007). Furthermore, the ts
lesion in the transfected nsp4 does not behave as a dominant negative as there was no
difference in viral output in WT‐A59 icv or Alb ts6 icv infected cells transfected with
nsp4‐N258T‐GFP incubated at the non‐permissive temperature (Figure 15).
Confocal analysis of nsp4‐GFP and nsp4‐N258T‐GFP localization with the ER or
mitochondria in the absence of infection demonstrated that, at both the permissive and
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Figure 15. Complementation analysis by ectopic expression of wildtype and mutant
nsp4. Two sets of DBT cells were transfected with vector, nsp4‐GFP, or nsp4‐N258T‐
GFP for 16 hours then infected with WT‐A59 icv or Alb ts6 icv for 24 hours. One set
was incubated at the permissive temperature and the other at the non‐permissive
temperature. Supernatants were collected and titrated on DBT cells incubated at the
permissive temperature. Plaques were counted 48 hours post infection. Gray bars,
WT‐A59 icv; White bars, Alb ts6 icv. Performed in triplicate; error bars indicate
standard deviation from the mean.
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non‐permissive temperature, both proteins localize with the ER and not the
mitochondria (Figure 16). Collectively, these data point to p150 as the protein affected
by the ts lesion; however, they do not definitively rule out the ts lesion affecting mature
nsp4. Cloning of p150 has been complicated by the instability of this region of the MHV
genome when cloned into plasmid DNA (Yount, et al., 2002). Cloning of p150 was
nevertheless attempted, but a stable clone of full‐length p150 could not be maintained.
Thus, complementation and confocal analysis could not be performed with exogenous
expression of p150.
Overall, these studies provide experimental evidence in support of a role of p150
and/or nsp4 in assembly of DMVs. Since the localization of other replicase proteins was
affected by the localization of nsp4, the hypothesized role of nsp4 as a scaffold protein
for replicase assembly is also supported by these data. Furthermore, glycosylation of
nsp4 at two asparagine residues was verified, and glycosylation of nsp4 at N176 is not
essential for the function of nsp4 and has no effect on MHV replication.

IFN ANTAGONISM BY PLPS
Aside from nsp4, there are two other integral membrane non‐structural proteins
encoded by coronaviruses, nsps 3 and 6. Very little is known about the function of nsp6.
In contrast, nsp3 has been studied quite extensively. A clear function of nsp3 was
demonstrated when the PLPs were identified. The papain‐like protease domain(s)
encoded within nsp3 cleave the N‐terminus of the polyprotein. Aside from this role in
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Figure 16. Localization of wildtype and mutant nsp4 with ER or mitochondria. Two
sets of BHK‐T7 cells were plated on 8 well permanox treated chamber slides and
transfected with nsp4‐GFP or nsp4‐N258T‐GFP. One set was incubated at the
permissive temperature and the other at the non‐permissive temperature. At 24
hours post transfection, cells were labeled with anti‐PDI and AF568 to detect ER or
MitoTracker to detect mitochondria shown in red. The GFP fused to the construct is
autofluorescent and is green. Cells were imaged on the Zeiss 510 confocal
microscope.
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coronavirus infection, PLPs from MHV, SARS‐CoV, and HCoV‐NL63 have been shown to
possess DUB activity and the ability to antagonize type I IFN induction. Unlike MHV
PLP2, PLpro from SARS‐CoV and PLP2 from HCoV‐NL63 could antagonize type I IFN
induction independently of catalytic activity; however, the mechanism(s) of inhibition
are unclear.

Characterization of PLP‐mediated Inhibition of ISRE‐Luc, NF‐κB‐Luc, and IFN‐β‐Luc
To determine the ability of SARS‐CoV PLpro and HCoV‐NL63 PLP2 to antagonize
the activity of IRF‐3, NF‐κB, and IFN‐β, HEK293 cells were transfected with plasmids
expressing either the soluble or the TM versions of PLpro or PLP2 at two concentrations
along with ISRE‐Luc, NF‐κB‐Luc, or IFN‐β‐Luc. Renilla luciferase, under the control of the
herpes simplex thymidine kinase promoter, was used as a transfection control and N‐
RIG was used to stimulate the ISRE‐Luc and IFN‐β‐Luc, whereas TNF‐α was used to
stimulate NF‐κB‐Luc. As shown in Figure 17, PLpro in both the soluble and TM form was
able to dose‐dependently inhibit all three reporters. The TM version was generally
more effective than the soluble form in its antagonistic capacity. Likewise, PLP2 was
found to antagonize all three reporters, with the TM being slightly more effective.
Devaraj et al. demonstrated that the catalytic cysteine mutant of PLpro‐TM was
able to dose‐dependently inhibit IFN‐β‐Luc; however, the cysteine mutant in the soluble
form was unable to effectively inhibit IFN‐β‐Luc reporter activity. In contrast, the
catalytic aspartic acid mutant was a potent IFN antagonist in both the soluble and TM
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Figure 17. Inhibition of IFN‐β‐Luc, ISRE‐Luc, and NF‐κB‐Luc by PLPs. HEK293 cells
were transfected with the indicated amounts PLPs along with IFN‐β‐Luc (A), ISRE‐Luc
(B), NF‐κB‐Luc (C), and pRL‐TK reporter. N‐RIG was used to stimulate IFN‐β and ISRE.
TNF‐α (10 ng/mL) was used to stimulate the NF‐κB‐Luc reporter. Values are
expressed as percent of N‐RIG or TNF‐α stimulated luciferase controls set to 100.
Error bars indicate standard deviation from the mean from triplicates.
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form (Devaraj, et al., 2007). To determine if HCoV‐NL63 PLP2 catalytic mutants are also
IFN antagonists, similar dose‐response reporter assays were performed. As seen in
Figure 18, all members of the catalytic triad can be mutated to alanine in either the
soluble or TM form and still dose‐dependently antagonize IFN‐β‐Luc reporter activity.
These data collectively suggest that catalytic activity contributes to IFN
antagonism as the catalytic cysteine mutant, which is devoid of all catalytic activity, is
less potent than wildtype, but enzymatic activity is not strictly required. To extend
these findings, a protease inhibitor (GRL‐0617S) that has been developed and shown to
specifically and selectively block protease and DUB activity of SARS‐CoV PLpro was
added to PLpro‐TM transfected cells, and the ability of PLpro‐TM to inhibit activation of
IFN‐β‐Luc, ISRE‐Luc, or NF‐κB‐Luc reporter activity was determined. HEK293 cells were
transfected with plasmid DNA encoding the transmembrane form of PLpro‐TM and pRL‐
TK along with the IFN‐β, ISRE, or NF‐κB reporter, and an nsp2/3‐GFP substrate. At the
time of transfection, the cells were treated with 100 μM of GRL‐0617S (10 times the
EC50) or DMSO (vehicle control). At 24 hours after transfection, cell lysates were
generated and evaluated for induction of the reporters and proteolytic processing of the
nsp2/3 substrate. As depicted in Figure 19, inhibition of protease activity by GRL‐0617S
had no effect on the IFN‐β reporter and little to no effect on the ISRE reporter that is
dependent on IRF‐3. An alleviation of PLpro‐mediated inhibition of the NF‐κB reporter
by GRL‐0617S was detected (compare Figure 19A and B with C). These results indicate
that protease/DUB activity may be important for PLpro‐mediated inhibition of NF‐κB
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Figure 18. Inhibition of IFN‐β‐Luc by wildtype and catalytic mutants of PLP2‐SOL (A)
and PLP2‐TM (B). HEK293 cells were transfected with the indicated amounts of PLPs
along with IFN‐β‐Luc and pRL‐TK reporters. N‐RIG was used to stimulate IFN‐β
induction. At 24 hours post transfection, cell lysates were harvested and assayed for
luciferase activity via the dual luciferase reporter assay. Values are expressed as
percent of N‐RIG stimulated luciferase controls set to 100. Error bars indicate
standard deviation from the mean from triplicates.
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Figure 19. SARS‐CoV PLpro inhibits IFN‐β and ISRE but not NF‐κB reporter activity in a
dose‐dependent manner in the presence or absence of a protease inhibitor. HEK293
cells were transfected with the indicated amounts PLpro‐TM along with IFN‐β‐Luc
(A), ISRE‐Luc (B), NF‐κB‐Luc (C), and pRL‐TK reporters and an nsp2/3‐GFP substrate.
N‐RIG was used to stimulate IFN‐β and ISRE. TNF‐α (10 ng/mL) was used to stimulate
the NF‐κB‐Luc reporter. DMSO vehicle control or 100 μM of GRL‐0617S was added at
the time of transfection. At 24 hours post transfection, cell lysates were harvested
and assayed for luciferase activity via the dual luciferase reporter assay. Values are
expressed as percent of N‐RIG or TNF‐α stimulated luciferase controls set to 100.
Error bars indicate standard deviation from the mean from triplicates. (D) Cell
lysates from above were mixed with 2X sample buffer and subjected to 12.5% SDS‐
PAGE. Following transfer to nitrocellulose, the membrane was blotted with mouse
anti‐V5 to detect PLpro‐TM and rabbit anti‐GFP to detect the nsp2/3‐GFP substrate
and the nsp3‐GFP cleavage product.
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activity but not essential for inhibition of IRF‐3 activity and thus IFN‐β. To demonstrate
the efficacy of the protease inhibitor, cell lysates used in the reporter assay were
assessed for nsp2/3‐GFP substrate cleavage. The nsp2/3‐GFP substrate contains a
region of nsp2/nsp3 (including the cleavage site) fused in‐frame with GFP and was
previously shown to be a substrate for PLpro (Frieman, et al., 2009). As shown in Figure
19D, the nsp3‐GFP cleavage product was readily detected in cell lysates that contain
PLpro in the absence of GRL‐0617S. In contrast, the processing of nsp2/3‐GFP and
liberation of nsp3‐GFP was almost completely abrogated in the presence of the drug.
Overall, these data provide further support that there is a catalysis‐independent
component to type I IFN antagonism by the papain‐like proteases of human
coronaviruses.

DUB Activity and IFN Antagonism
Given the involvement of ubiquitination in the type I IFN induction cascade, the
fact that PLpro has DUB activity, and the reduced IFN antagonism by the catalytic
cysteine mutant that is devoid of DUB activity, it is reasonable to hypothesize that DUB
activity is involved in the mechanism of IFN antagonism. This notion is supported by the
IFN antagonism profile of the catalytic aspartic acid mutant. This mutant has a
significant defect in polyprotein processing, but near wildtype DUB activity (Kiira Ratia,
dissertation). This mutant can antagonize IFN‐β‐Luc reporter activity similar to wildtype
PLpro or PLP2 suggesting that DUB activity is a significant contributing factor.
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To determine if HCoV‐NL63 PLPs have DUB activity like PLpro, HEK293 cells were
transfected with FLAG‐tagged Ub in the presence of increasing amounts of either PLP1
or PLP2. Only PLP2 was found to dose‐dependently reduce FLAG‐tagged Ub conjugation
to cellular substrates and this activity was dependent on catalytic activity as the cysteine
mutant lacked DUB activity (Clementz, et al., 2010). Ubiquitin is conjugated to cellular
proteins by covalent attachment to a lysine residue on the target protein. Ubiquitin
contains seven lysines upon which another ubiquitin molecule can be attached, forming
different types of polyubiquitin‐linked chains on the target protein. The two most
common types of polyubiquitin chains are linked through ubiquitin lysine 48 (K48) and
lysine 63 (K63). These modifications play key regulatory roles in protein degradation
and pathway signaling, and have been associated with controlling several pathways of
innate and adaptive immunity (Bhoj and Chen, 2009). Previous studies indicated that
SARS‐CoV PLpro processes both K48‐ and K63‐linked ubiquitin (Lindner, et al., 2005;
Lindner, et al., 2007). To assess if HCoV‐NL63 PLP2 has isopeptidase activity that will
deconjugate K63‐linked ubiquitin in addition to K48‐linked isopeptidase activity, purified
PLP2 protein was incubated with hexameric K48‐linked and K63‐linked polyubiquitin
chains. SDS‐PAGE analysis of the cleavage products showed that PLP2 can cleave the
substrates in vitro, and with prolonged incubation times, both chains can be reduced to
mono‐ubiquitin demonstrating that both major forms of polyubiquitin can be
recognized and degraded by HCoV‐NL63 PLP2 (Clementz, et al., 2010).
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CATALYTIC‐INDEPENDENT ANTAGONISM OF TYPE I IFN INDUCTION
Since the catalytic mutants are still able to antagonize IFN‐β reporter activity,
particularly the catalytic cysteine mutant that has absolutely no enzymatic activity,
there is a catalytic‐independent mechanism that contributes to inhibition of type I IFN
induction. Data from Devaraj et al. demonstrated that PLpro and IRF‐3 associate via co‐
immunoprecipitation experiments; however, Frieman et al. report that PLpro and IRF‐3
do not directly interact. Therefore, it is plausible that other cellular proteins that
interact with IRF‐3 could be bridging the gap between PLpro and IRF‐3.

Alanine Scanning Mutagenesis and Characterization of PLpro Mutants
To identify this unknown host factor, pull‐down experiments followed by mass
spectrometry were planned. One desirable component to facilitate finding this
unknown protein would be to have a loss of function mutant of PLpro, which would
presumably have lost the ability to interact with this unknown factor, to be used as a
negative control. Given that the crystal structure of PLpro was solved by Ratia et al., an
initial alanine scan of surface residues was performed to potentially identify any
mutants that have lost IFN antagonism (Naina Barretto, unpublished data). Since loss of
IFN antagonism could be due to gross misfolding, only mutants that retained catalytic
activity were analyzed. Out of one deletion mutant and 21 point mutants, two were
identified that had a moderate loss of IFN antagonism but retained proteolytic activity.
These mutants are R1768A and E1719A (counting residues from ORF1a).
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To determine if simultaneous mutation of these residues would further reduce
IFN antagonism, the E1719A mutation was introduced into the R1768A mutant to
generate the R1768A/E1719A double mutant using site‐directed mutagenesis. As seen
in Figure 20, mutation of both residues has no effect on IFN antagonism as compared to
wildtype. These results prompted a re‐evaluation of the R1768A and E1719A single
mutants. The single mutants were engineered into soluble PLpro as well as PLpro‐TM.
PLpro contains a domain that bears remarkable similarity to Ub termed the ubiquitin‐
like domain (Ubl). This domain was found to be necessary for IFN antagonism by
Frieman et al.; however, I’ve found that the loss of the Ubl domain has no effect on IFN
antagonism (Figure 21). The R1768A and E1719A single and double mutants were also
tested in the ΔUbl‐PLpro construct as well. As shown in Figure 22, the R1768A and
E1719A single or double mutants in any of the PLpro constructs tested were as effective
as wildtype in inhibiting N‐RIG‐induced IFN‐β‐Luc reporter activity.

Mass Spectrometry Analysis of PLpro Interacting Proteins
Since a PLpro loss of function mutant could not be attained, a newly developed
technology that allows for efficient identification of protein‐protein interactions was
employed. The HaloTag technology is based on a polypeptide that can be fused to
proteins of interest. This polypeptide is a hydrolase derivative that makes permanent
covalent bonds with a number of known ligands, including HaloMAG magnetic beads.
HEK293 cells were transfected with PLpro‐HALO or HALO vector alone, which will
express the PLpro‐HALO fusion protein or the HALO polypeptide respectively. Cells
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Figure 20. Inhibition of IFN‐β‐Luc by PLpro‐SOL and PLpro‐TM wildtype and
R1768A/E1719A double mutants. HEK293 cells were transfected with the indicated
amounts of PLpro along with IFN‐β‐Luc and pRL‐TK reporters. N‐RIG was used to
stimulate IFN‐β induction. At 24 hours post transfection, cell lysates were harvested
and assayed for luciferase activity via the dual luciferase reporter assay. Values are
expressed as percent of N‐RIG stimulated luciferase controls set to 100. Error bars
indicate standard deviation from the mean from triplicates.
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Figure 21. The ubiquitin‐like domain of SARS‐CoV PLpro is not required for IFN
antagonism. (A) HEK293 cells were transfected with the indicated amounts PLpro‐
Sol, ΔUbl‐PLpro‐Sol, or ΔUbl‐PLpro‐TM along with IFN‐β‐Luc and pRL‐TK reporters. A
dominant active N‐terminal portion of RIG‐I was used to stimulate IFN‐β induction.
At 24 hours post transfection, cell lysates were harvested and assayed for luciferase
activity via the dual luciferase reporter assay. Values expressed are relative to cells
transfected with the reporters alone. Error bars indicate standard deviation from the
mean from triplicates. (B) Cell lysates from above were mixed with 2X sample buffer
and western blotted with mouse anti‐V5 to detect the proteases and anti‐actin as a
loading control.
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Figure 22. Inhibition of IFN‐β‐Luc by PLpro‐SOL, PLpro‐TM, ΔUbl‐PLpro‐TM wildtype
and R1768A and/or E1719A mutants. HEK293 cells were transfected with the
indicated amounts of PLpro along with IFN‐β‐Luc and pRL‐TK reporters. N‐RIG was
used to stimulate IFN‐β induction. At 24 hours post transfection, cell lysates were
harvested and assayed for luciferase activity via the dual luciferase reporter assay.
Values are expressed as percent of N‐RIG stimulated luciferase controls set to 100.
Error bars indicate standard deviation from the mean from triplicates.
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were lysed in TLB and incubated with HaloMAG magnetic beads to immobilize PLpro‐
HALO or the HALO polypeptide along with any cellular proteins that bind to these
proteins. The captured cellular proteins were eluted by addition of 1X Laemmli Buffer
and incubation at 90°C for 10 minutes. The eluted proteins were separated by SDS‐
PAGE and visualized by silver stain. As seen in Figure 23, very few cellular proteins
interact with the HALO polypeptide alone, whereas a large number of proteins interact
with PLpro. Several attempts were made to minimize the number of cellular proteins
captured by PLpro‐HALO. For example, the ability of PLpro to interact with so many
proteins could be due to its ability to deubiquitinate proteins. In this way, PLpro is
actually interacting with Ub conjugated to the captured cellular proteins. Thus, the
catalytic mutant was tested, but showed no qualitative difference in captured cellular
proteins. Other optimization attempts included trying different detergents (digitonin,
NP40, or Tween 20 in the place of Triton X‐100) and more washes; however, large
numbers of cellular proteins were nonetheless captured.
Mass spectrometry was performed on the cleanest pull‐down experiment. The
control and experimental samples were separated by SDS‐PAGE and each lane was cut
from the gel. The large gel slice was further cut into three pieces of identical size,
destained, and sent to University of Arizona Proteomics Consortium for identification. A
large number of proteins were identified at high confidence, but none that are known
key players in the IFN induction signaling cascade. A full list of identified proteins is
included in the appendix.
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Figure 23. Silver stain of HaloTag or PLpro‐HALO pull downs. HEK293 cells were
transfected with HaloTag vector alone or PLpro‐HALO. The HALO polypeptide or
PLpro‐HALO was immobilized by covalent attachment to the HaloMAG magnetic
beads. Beads were extensively washed and incubated with 1X Laemmli Buffer at
90°C for 10 minutes. Eluted proteins were run on SDS‐PAGE and visualized by silver
stain. Each lane was cut into thirds, destained, and sent for identification via mass
spectrometry.
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INHIBITION OF STING BY THE PLPS
About the same time as I was cloning PLP2 from HCoV‐NL63 into the HaloTag
vector, a former postdoc in and current collaborator with the Baker lab, Zhongbin Chen
and his lab, identified STING as a PLP2‐TM interacting protein. To confirm these results
and determine if SARS‐CoV PLpro could interact with STING, co‐immunoprecipitation
experiments were performed. HEK293 cells were transfected with 2 μg of STING‐HA
and/or 2 μg of PLpro‐V5 or PLP2‐V5. Cell lysates were prepared in ELB and precleared
by incubation with protein G magnetic beads. STING was immunoprecipitated in
precleared lysates by incubation with 2 μg of rabbit anti‐HA antibody and protein G
magnetic beads. Following washing, the proteins were eluted from the beads and run
on SDS‐PAGE. Following transfer to nitrocellulose, the membrane was blotted with
mouse anti‐HA to detect STING‐HA and mouse anti‐V5 to detect the PLPs. As seen in
Figure 24, both PLpro‐V5 and PLP2‐V5 associate with STING‐HA.
To determine if the catalytic cysteine mutants of the PLPs can also associate with
STING, similar co‐immunoprecipitation experiments were performed. As seen in Figure
25, the catalytic cysteine mutants of both PLpro and PLP2 can associate with STING.
Given that the PLPs potently affect IRF‐3 activation, even the catalytically inactive PLPs,
and STING has been shown to be intimately involved in the activation of IRF‐3, the PLPs
could be associating with and interfering with the activity of STING. This could
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Figure 24. Co‐immunoprecipitation of STING and PLPs. HEK293 cells were
transfected with 2 μg of STING‐HA and 2 μg of either PLpro‐V5 (A) or PLP2‐V5 (B).
Cells were lysed in ELB and precleared with protein G magnetic beads. Precleared
lysate was incubated with rabbit ant‐HA and protein G magnetic beads. Following
overnight incubation at 4°C, beads were washed three times with cold ELB and
immunoprecipitated proteins were eluted by incubation at 37°C for 30 minutes in 1X
Laemmli Buffer. Samples were run on SDS‐PAGE and western blotted with mouse
anti‐HA and mouse anti‐V5 to detect STING‐HA and PLPs‐V5 respectively.
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Figure 25. Co‐immunoprecipitation of STING and catalytic mutant PLPs. HEK293 cells
were transfected with 2 μg of STING‐HA and 2 μg of either PLpro‐C1651A‐V5 (A) or
PLP2‐C1678A‐V5 (B). Cells were lysed in ELB and precleared with protein G magnetic
beads. Precleared lysate was incubated with rabbit ant‐HA and protein G magnetic
beads. Following overnight incubation at 4°C, beads were washed three times with
cold ELB and immunoprecipitated proteins were eluted by incubation at 37°C for 30
minutes in 1X Laemmli Buffer. Samples were run on SDS‐PAGE and western blotted
with mouse anti‐HA and mouse anti‐V5 to detect STING‐HA and PLPs‐V5 respectively.
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Figure 26. Co‐immunoprecipitation of full length or truncated STING and PLPs.
HEK293 cells were transfected with 2 μg of STING‐HA full length (FL) or the C‐
terminal domain of STING lacking the TM domains (CT) and/or 2 μg of PLpro‐SOL,
PLpro‐TM, PLP2‐SOL, or PLP2‐TM. Cells were lysed in ELB and precleared with
protein G magnetic beads. Precleared lysate was incubated with rabbit ant‐HA and
protein G magnetic beads. Following overnight incubation at 4°C, beads were
washed three times with cold ELB and immunoprecipitated proteins were eluted by
incubation at 37°C for 30 minutes in 1X Laemmli Buffer. Samples were run on SDS‐
PAGE and western blotted with mouse anti‐HA and mouse anti‐V5 to detect STING‐
HA and PLPs‐V5 respectively.
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potentially explain how, mechanistically, the PLPs inhibit type I IFN induction and
possibly how the catalytic mutants inhibit without DUB activity.
To begin to identify which portions of STING and the PLPs are necessary for
interaction, the TM domains of either the PLPs and/or STING were removed, essentially
cutting each protein in half, and all combinations were tested for association by co‐
immunoprecipitation. As seen in Figure 26, both the soluble and TM forms of both
PLpro and PLP2 can associate with full length STING. Interestingly, only the TM forms of
the PLPs could associate with the C‐terminal portion of STING lacking the N‐terminal TM
domains.
To determine if PLP2‐TM and the catalytic cysteine mutant are able to inhibit
STING‐induced activation of IRF‐3, HEK293 cells were transfected with the pISRE‐
luciferase and pRL‐TK renilla luciferase reporters with or without STING‐HA and three
concentrations of PLP2‐TM or PLP2‐TM C1678A and luciferase activity was determined
by the dual luciferase reporter assay. As demonstrated in Figure 27, PLP2‐TM was able
to dose‐dependently inhibit STING‐induced activation of IRF‐3. Likewise, PLP2‐TM
C1678A was able to inhibit the activation of the pISRE reporter in a dose‐dependent
manner, but similar to N‐RIG‐stimulated cells, the catalytic mutant was less effective.
Similar results were obtained for PLpro‐TM and PLpro‐TM C1651A (Sun et al.,
manuscript in preparation).
It was demonstrated that STING dimerizes upon activation and that dimerization
is critical for STING‐mediated activation of IRF‐3 (Sun, et al., 2009). To determine if
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Figure 27. Inhibition of STING‐mediated activation of ISRE‐Luc. (A) HEK293 cells
were transfected with the indicated amounts PLP2‐TM or PLP2‐TM C1678A along
with ISRE‐Luc and pRL‐TK reporters. STING‐HA was used to stimulate ISRE‐Luc
induction. At 24 hours post transfection, cell lysates were harvested and assayed for
luciferase activity via the dual luciferase reporter assay. Values expressed are
relative to cells transfected with the reporters alone. Error bars indicate standard
deviation from the mean from triplicates. (B) Cell lysates from above were mixed
with 2X sample buffer and western blotted with mouse anti‐V5 to detect the
proteases and mouse anti‐HA to detect STING‐HA.
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association of the PLPs with STING interferes with STING dimer formation, HEK293 cells
were transfected with 2 μg of STING‐HA and increasing amounts of PLP2‐TM‐V5 or
PLP2‐TM‐V5 C1678A. STING‐HA was immunoprecipitated as described before and
subjected to western blot to detect STING and PLP2‐TM. As shown in Figure 28,
expression of increasing amounts of PLP2‐TM resulted in a concomitant reduction in the
amount of STING‐HA dimer. A slight effect on the levels of STING dimer was detected
by increasing amounts of the catalytic cysteine mutant, but consistent with the
luciferase reporter data, the catalytic mutant was less effective than wildtype. Sun et al.
reported that only the dimer form of STING was ubiquitinated, which may explain why
wildtype PLP2‐TM that has DUB activity is more effective at inhibiting STING dimer than
the catalytically inactive mutant (2009). Similar results were also obtained for SARS‐CoV
PLpro‐TM and PLpro‐TM C1651A (Sun et al., manuscript in preparation).
In order for IRF‐3 to influence gene transcription, it needs to translocate to the
nucleus. It has been shown that SARS‐CoV PLpro can inhibit the nuclear translocation of
IRF‐3 (Devaraj, et al., 2007). The inhibition of STING by PLP2‐TM should result in a loss
of IRF‐3 activation. To determine if the nuclear translocation of IRF‐3 is inhibited by
PLP2‐TM, HEK293 cells were plated on fibronectin treated glass cover slips and
transfected with STING‐HA in the presence or absence of PLP2‐TM‐V5. Cells were
processed for immunofluorescence and stained with antibodies against the HA and V5
epitope tags as well as an antibody to endogenous IRF‐3. As demonstrated in Figure 29,
STING‐HA‐induced nuclear translocation of endogenous IRF‐3 was inhibited in the
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Figure 28. Inhibition of STING dimer by PLP2‐TM and PLP2‐TM C1678A. HEK293 cells
were transfected with 2 μg of STING‐HA and 2 μg of either PLP2‐TM‐V5 (A) or PLP2‐
TM‐C1678A‐V5 (B). Cells were lysed in ELB and precleared with protein G magnetic
beads. Precleared lysate was incubated with rabbit ant‐HA and protein G magnetic
beads. Following overnight incubation at 4°C, beads were washed three times with
cold ELB and immunoprecipitated proteins were eluted by incubation at 37°C for 30
minutes in 1X Laemmli Buffer. Samples were run on SDS‐PAGE and western blotted
with mouse anti‐HA and mouse anti‐V5 to detect STING‐HA and PLPs‐V5 respectively.
N.S. = Non‐Specific band.
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Figure 29. Inhibition of STING‐mediated nuclear translocation of IRF‐3. (A) HEK293
cells were plated on fibronectin treated glass cover slips and transfected with 225 ng
STING‐HA in the presence or absence of 300 ng of PLP2‐TM. At 16 hours post
transfection, cells were processed for imaging with the Zeiss LSM‐510 confocal
microscope. (B) Panels from A in which PLP2‐TM‐V5 is colored green and IRF‐3 is
omitted to demonstrate PLP2‐TM‐V5 and STING‐HA co‐localization.

90
presence of PLP2‐TM‐V5. Consistent with the association of PLP2‐TM‐V5 and STING‐HA
via co‐immunoprecipitation, these two proteins almost completely co‐localize in the
cell.
These data collectively suggest that the PLPs are IFN antagonists and that
catalytic activity contributes to, but is not strictly required for IFN antagonism. DUB
activity is the most likely contribution of catalytic activity in the inhibition of type I IFN
induction. The PLPs can associate with STING and can inhibit the dimerization of STING,
which is essential for IRF‐3 activation. In line with this, PLPs inhibit the nuclear
accumulation of IRF‐3, a requisite for induction of type I IFNs.

CHAPTER IV
DISCUSSION

nsp4 IN MHV REPLICATION
The coronavirus replicase is a complex multiprotein assembly that carries out
both mRNA transcription as well as genomic RNA replication. The function of some
replicase proteins has been elucidated, particularly those that have enzymatic activity.
There are two classes of proteases encoded by the coronavirus replicase: papain‐like
proteases (one or two PLP domains) and a 3C‐like protease found within nsp3 and nsp5
respectively (Baker, et al., 1989; Gorbalenya, et al., 1989; Kanjanahaluethai and Baker,
2000; Kanjanahaluethai and Baker, 2001; Lee, et al., 1991). The PLP domains have also
been shown to cleave more than just the polyprotein and can catalyze the removal of
both Ub and ISG15 (Barretto, et al., 2006; Barretto, et al., 2005; Lindner, et al., 2005;
Lindner, et al., 2007). nsp8 and nsp12 have been found to catalyze the polymerization
of RNA (Cheng, et al., 2005; Imbert, et al., 2006). The last four nsps, nsps 13‐16, have
helicase (nsp13), exonuclease (nsp14), endoribonuclease (nsp15), and
methyltransferase activity (nsp16) (Bhardwaj, et al., 2004; Decroly, et al., 2008; Ivanov,
et al., 2004a; Ivanov, et al., 2004b; Ivanov and Ziebuhr, 2004; Ricagno, et al., 2006).
Other nsps, nsp7, nsp8, nsp9, and nsp10 can bind to RNA, but the full functions
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of these proteins are still unclear (Matthes, et al., 2006; Sutton, et al., 2004; Zhai, et al.,
2005).
A hallmark of RNA virus replication is the modification of host cell membranes
upon which viral replication complexes assemble (Salonen, et al., 2005). Of the 16 nsps
generated in coronavirus infected cells, three of them are integral membrane proteins,
nsp3, nsp4, and nsp6 (Baliji, et al., 2009; Oostra, et al., 2008; Oostra, et al., 2007). These
proteins are the likely candidates that mediate host membrane rearrangements, which
for coronaviruses are DMVs (Gosert, et al., 2002; Knoops, et al., 2008). In fact, the
homologs of nsp3 and nsp4 in coronaviruses are nsp2 and nsp3 in EAV, which have been
shown to be necessary and sufficient to induce DMV formation (Snijder, et al., 2001).
Aside from the membrane topology and glycosylation status, very little is known about
the functions of nsp4 and nsp6 in coronavirus infection. nsp4 is critical for viral
replication, especially the amino terminal portion upstream of the fourth TM domain
(Sparks, et al., 2007). Given its membrane integration, its DMV localization, and the EAV
homolog is involved in DMV formation, nsp4 was hypothesized to be involved in DMV
and/or viral replicase assembly (Gosert, et al., 2002).
Work presented in this dissertation furthers current knowledge of the function
of nsp4 in MHV replication. Glycosylation of nsp4 at asparagine residues 176 and 237 in
the region that lies between TM1 and TM2 was experimentally verified (Clementz, et al.,
2008). The necessity for glycosylation of these sites in viral replication was then
assessed by engineering asparagine to alanine mutations in MHV ic virus using reverse
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genetics. MHV ic virus for wildtype and N176A were recovered, but despite several
attempts, the N237A and N176A/N237A viruses could not be generated suggesting that
glycosylation of N237 is important for MHV replication. It has been recently determined
that the N237A and N176A/N237A are viable, but they are significantly impaired in viral
replication and RNA synthesis (Gadlage, et al., 2010). Mutation of N176A had no effect
on viral replication as titers of wildtype icv and nsp4‐N176A icv were equivalent at all
time points post infection analyzed (Clementz, et al., 2008). This conclusion was verified
by the group that isolated the other glycosylation mutants (Gadlage, et al., 2010).
The importance of the luminal portion of nsp4 was demonstrated by analyzing a
temperature sensitive mutant within this region. The mutation was originally identified
by Sawicki and co‐workers who analyzed the sequence of 19 MHV ts mutants and
reported that one of these mutant viruses, Alb ts6, encoded a substitution of asparagine
for threonine at nsp4‐258. They hypothesized that this mutation alone was sufficient to
confer the ts and RNA synthesis‐negative phenotype to MHV‐A59; however, the
presence of other mutations within the chemically mutagenized isolate prohibited a
definitive determination. Via reverse genetics, I engineered the nsp4‐N258T mutation
into an otherwise wildtype MHV background and determined if this mutation alone
conferred temperature sensitivity. The isolated virus, named Alb ts6 icv, was indeed
temperature sensitive. Titers were reduced approximately 5 orders of magnitude when
incubated at the non‐permissive temperature; however, Alb ts6 icv titers at 33°C were
comparable to WT‐A59 icv (Figure 11). Growth kinetics, assayed by a one‐step growth
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curve at the permissive temperature, were indistinguishable between Alb ts6 icv and
WT‐A59 icv. When Alb ts6 icv infected cells were first incubated at the permissive
temperature and then shifted to the non‐permissive temperature six hours post
infection, titers fell 1000 fold by 12 hours post infection (Clementz, et al., 2008).
Using a similar reverse genetics approach, Donaldson et al. found that a single
amino acid substitution in nsp10 conferred temperature sensitivity to the resulting icTS‐
LA6 virus, another ts lesion implicated in the study by Sawicki et al. (2007). Analysis of
the defect induced by the ts lesion revealed that nsp10 is a necessary cofactor for
3CLpro activity as proteolytic processing of the replicase intermediate p150 was
defective in icTS‐LA6 infected cells incubated at the non‐permissive temperature. In
contrast, the Alb ts6 icv had no defects in the proteolytic processing of p150 when virus
infected cells were incubated at the non‐permissive temperature (Clementz, et al.,
2008).
In light of the suggested role of nsp4 in DMV and/or replicase assembly, DMV
formation in wildtype icv or Alb ts6 icv was assessed at the ultrastructural level via TEM.
This analysis revealed that DMV assembly was severely impaired in the Alb ts6 icv
infected cells incubated at the non‐permissive temperature (Figure 12). The failure to
assemble DMVs, which are the site of viral RNA synthesis, is consistent with the RNA
minus phenotype observed by Sawicki et al. (2005). Also, TEM analysis of Alb ts6 icv
infected cells incubated at the non‐permissive temperature showed a disruption of
mitochondrial morphology; the mitochondria were enlarged and extensively vacuolated
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(Figure 12). Using confocal microscopy, I assessed whether nsp4‐N258T was localized to
the mitochondria. nsp4‐N258T partially co‐localized with mitochondria in virus infected
cells incubated at the non‐permissive temperature (Figures 13 and 14). Interestingly,
nsp3 also showed increased co‐localization with mitochondria, suggesting that nsp4 may
direct the localization of other replicase components, which is consistent with a
predicted role of nsp4 in replicase assembly (Figures 13 and 14).
Currently, it is unclear if the ts lesion is affecting the p150 intermediate, the
mature nsp4 protein, or both. To begin to address this issue, complementation studies
were performed. Exogenous expression of nsp4‐GFP could not restore viral titers in Alb
ts6 icv infected cells incubated at the non‐permissive temperature suggesting that
mature nsp4 cannot complement the defect in Alb ts6 icv infected cells. Oostra et al.
demonstrated that nsp4‐GFP was recruited to replicase complexes suggesting that
transfected nsp4 is functional (2007). nsp4‐N258T‐GFP does not behave as a dominant
negative in that viral output was the same in WT‐A59 icv or Alb ts6 icv infected cells
transfected with nsp4‐N258T‐GFP and incubated at the non‐permissive temperature
(Figure 15). Other than co‐localization of nsp4‐GFP with other viral replicase proteins in
MHV infected cells, there was no other demonstration of the functionality of the nsp4
construct. Therefore, it is formally possible that the defect could be complemented by
mature nsp4.
Despite this caveat, complementation analysis using virus argues that the ts
lesion is affecting p150. For example, a virus with a mutation in nsp10 (TS‐LA6) crossed
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with a nsp4 mutant (Alb ts6) do not complement each other (Sawicki, et al., 2005).
Since the TS‐LA6 virus has a defect in p150 processing, it is clear why this mutant cannot
complement Alb ts6 as mature nsp4 is never liberated from the TS‐LA6 virus. The
converse is not as clear. Since Alb ts6 icv has no defect in processing p150, nsp10 is
liberated and should in theory complement the defect in TS‐LA6. This is not the case
though suggesting that p150 is affected as neither virus can contribute a functional p150
protein.
To determine if an alteration in localization of nsp4 could be identified in the
absence of viral infection, confocal analysis of nsp4‐GFP and nsp4‐N258T‐GFP
localization with the ER or mitochondria at both the permissive and non‐permissive
temperature was performed. Both nsp4‐GFP and nsp4‐N258T‐GFP localized with the ER
and not the mitochondria at either temperature. One caveat to these experiments is
that the other viral proteins may be required for localization of nsp4‐N258T‐GFP to the
mitochondria, particularly if DMVs are being misdirected to the mitochondria, which are
not formed by exogenous expression of nsp4.
These data collectively point to the ts lesion affecting p150. Cloning of p150 was
attempted, but a full‐length clone of p150 could not be stably maintained. This is likely
due to the inherent instability of this region of the MHV genome when cloned into
plasmid DNA (Yount, et al., 2002). Thus, complementation and confocal analysis with
exogenously expressed p150 could not be performed. Perhaps with the development of
new vectors capable of stable maintenance of hard to clone regions, p150 or larger
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pieces of the region encoding the polyprotein could be cloned. It would be interesting
to test an nsp3‐4 expression construct for the ability to form DMVs, similar to the
homologs in EAV nsp2‐3.
The aberrant mitochondrial morphology and partial co‐localization of
mitochondria with nsp3 and nsp4 raises questions about the role for mitochondria in
MHV replication. Could nsp4‐N258T be localizing to mitochondria in error resulting in
reduced DMV assembly? Or is there a mitochondrial phase in MHV replication whose
progression is inhibited by the nsp4‐N258T substitution? Two reports suggest an
interaction between MHV infection and the mitochondria. It was demonstrated by
Nanda et al. that the mitochondrial matrix protein m‐aconitase co‐localizes with
coronavirus N protein and can bind to the 3’‐UTR of the MHV genome (2001). In this
study, a protein‐binding element in the 3’‐UTR was used to capture cellular proteins that
could bind to this nucleic acid sequence. Of the four proteins that bound the RNA, only
m‐aconitase was unequivocally indentified. A 70 kDa protein was putatively identified
as mitochondrial heat shock protein 70 (mtHSP70) and the other two proteins are yet
unidentified (Nanda and Leibowitz, 2001). Another study, using MHV as a model for
demylination of the CNS, found that MHV infection induces apoptosis in
oligodendrocytes specifically through the mitochondrial apoptotic pathway suggesting
an interplay between MHV infection and mitochondrial components (Liu, et al., 2006).
For some viruses, the replicase complex can be directed to use different
membrane sources for efficient virus replication. For example, Flock house virus (FHV)
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normally induces spherules within the outer membrane of the mitochondria providing
precedence for the use of mitochondrial membranes as the site of membrane‐bound
replication complex assembly (Kopek, et al., 2007; Miller and Ahlquist, 2002; Miller, et
al., 2001). To determine if mitochondrial membranes were required for replication,
Miller et al. (2003) replaced the mitochondrial outer membrane targeting signal of FHV
protein A with that of an ER targeting signal and measured viral replication. They found
that the ER‐targeted replication complex functioned as efficiently, if not more
efficiently, than the normal mitochondria‐targeted replication complex. Therefore, a
specific source of membranes for replication complex assembly is not required for FHV.
For MHV, and coronaviruses in general, the source of membranes used for DMV
formation is unclear. Most evidence suggests that they are derived from the ER;
however, some studies implicate an involvement of the autophagy in DMV assembly
(Prentice, et al., 2004; Snijder, et al., 2006). Future studies are necessary to fully
characterize the source of membranes as well as the involvement of the mitochondria in
coronavirus infection.
The ts lesion in the luminal region resulted in a clear impairment in the amount
of DMVs generated in Alb ts6 icv infected cells at the non‐permissive temperature. The
involvement of this portion of nsp4 (or p150) in DMV formation was further
corroborated by analysis of the N237A and N176A/N237A MHV ic mutant viruses, which
displayed aberrant DMV morphology (Gadlage, et al., 2010). In sum, the work
presented on nsp4 demonstrates that this integral membrane protein plays a critical
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role in DMV and/or viral replicase assembly contributing to our understanding of the
functions of the many coronavirus replicase proteins.

ANTAGONISM OF TYPE I IFN INDUCTION BY THE PAPAIN‐LIKE PROTEASES OF SARS‐
CoV AND HCoV‐NL63
In addition to its role in cleaving the polyprotein, nsp3 has been found to have
other activities in the cell. Work described in this dissertation enhances our
understanding of the multifunctional nature of the papain‐like protease domains of
NL63 and SARS coronaviruses. These coronavirus PLP domains act as viral proteases,
deubiquitinating/deISGylating enzymes, and are able to antagonize innate immune
induction of type I interferon. Using mutagenesis and pharmacological studies, it was
determined that PLP‐mediated interferon antagonism is enhanced by, but is not strictly
dependent on, the catalytic activity of the enzyme.
To identify the region(s) of the PLPs that are critical for IFN antagonism, alanine
scanning mutagenesis and deletion analysis has been performed. The goal of these
experiments was to identify loss of function mutants that could no longer associate with
the host cell protein(s) that wildtype PLPs inhibit. Since the structure of the core
domain of PLpro has been solved, charged surface residues that could potentially be
involved in associating with host factors can be accurately selected for mutagenesis.
Using this approach, two mutants (R1768A and E1719A) were initially identified that
showed a loss of antagonism activity. However, further dose‐response analysis of these
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mutants demonstrated that mutation of these two residues either singly or in
combination had no effect on the ability of these mutants to antagonize IFN induction.
So far, no loss of function mutants have been identified for HCoV‐NL63 PLP2 either. The
crystal structure of SARS‐CoV PLpro has also identified a unique domain that has
remarkable similarity to ubiquitin (Ratia, et al., 2006). Frieman and co‐workers reported
that removal of the Ubl domain in the soluble version of PLpro resulted in a loss of IFN
antagonism (Frieman, et al., 2009). However, the authors of that study assessed IFN
antagonism using one concentration of PLpro. By performing a dose‐response profile of
IFN antagonism, it was determined that deletion of the Ubl domain from both the
soluble and the transmembrane version of PLpro had no effect on IFN antagonism.
Thus, it is critical to assess the effect of IFN antagonism across a range of protein
concentrations to fully evaluate the activity of these proteases.
The recognition of the DUB/deISGylating activity of SARS‐CoV PLpro and HCoV‐
NL63 PLP2 provides new opportunities to investigate how the virus is modifying the host
cell environment. Post‐translational modification of proteins by ubiquitin and ubiquitin‐
like (Ubl) molecules, such as SUMO, ISG15, and Nedd8, plays a critical role in the
regulatory processes of virtually all aspects of cell biology (Evans, et al., 2004; Frias‐
Staheli, et al., 2007; Haglund and Dikic, 2005; Hicke and Dunn, 2003; Isaacson and
Ploegh, 2009; Kirkin and Dikic, 2007; Lenschow, et al., 2007; Liu, et al., 2005; Platanias,
2005). These modifications, though covalent, are highly reversible. Deubiquitinating
enzymes can deconjugate Ub and Ub‐like moieties, and thus modulate the activities of
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ubiquitinated proteins. There are about 100 DUBs encoded in the human genome and
most of the known DUBs are cysteine proteases, characterized by a Cys‐His‐Asp catalytic
triad (Nijman, et al., 2005). Several RNA viruses encode cysteine proteases to generate
mature viral proteins necessary for replication, and many have been found to be
multifunctional proteins. Like SARS‐CoV PLpro and HCoV‐NL63 PLP2, the protease of a
nairovirus, Crimean Congo hemorrhagic fever virus (CCHFV), and the proteases of
arteriviruses, including equine arteritis virus (EAV) and porcine respiratory and
reproductive syndrome virus (PRRSV) have DUB and deISGylase activity (Barretto, et al.,
2005; Frias‐Staheli, et al., 2007; Lindner, et al., 2005).
The contribution of these enzymatic activities toward inhibition of type I IFN
induction is just beginning to be understood. Ubiquitination is known to be intimately
involved in the activation of several key factors in the type I IFN cascade. For NF‐κB,
poly‐ubiquitination of receptor‐interacting protein (RIP), TNF receptor‐associated factor
6 (TRAF6), and TNF receptor‐associated factor 2 (TRAF2) activates these signaling
intermediates, which leads to the polyubiquitination of IκB. IκB, which binds to and
holds NF‐κB inactive in the cytoplasm, is degraded via the proteasome thereby freeing
NF‐κB to translocate to the nucleus and induce IFN‐β transcription (Brown, et al., 1995).
Pharmacological inhibition of PLpro catalytic activity abrogated the moderate inhibition
of NF‐κB reporter activity supporting a role for coronavirus DUBs in modulating the NF‐
κB response during coronavirus replication. However, further investigation is needed to
delineate the physiological effect of coronavirus PLPs on NF‐κB signaling, as SARS‐CoV
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PLpro did not inhibit virus‐ or dsRNA‐induced activation of two well‐characterized NF‐
κB‐dependent genes, IL‐6 and A20, when it was stably expressed in HeLa cells in a
tetracycline‐regulated fashion (Devaraj, et al., 2007).
Like NF‐κB, many key proteins involved in IRF‐3 activation are ubiquitinated. For
example, RIG‐I, MAVS TRIF, STING, TRAF3, TANK, TBK‐1 and IRF‐3 itself are
ubiquitinated, and PLP2‐TM has been shown to deconjugate Ub from RIG‐I, STING, TBK‐
1, and IRF‐3 (Sun et al. manuscript in preparation). The integral ER‐resident protein
STING has been identified as a potential target for PLP‐mediated inhibition of IRF‐3. The
soluble and TM version of the PLPs associate with STING as determined by co‐
immunoprecipitation and confocal analysis. A necessary step in STING‐mediated IRF‐3
activation is the dimerization of STING, which was found to be dose‐dependently
inhibited by the PLPs. The catalytic mutant was less effective at reducing STING dimer
perhaps reflecting a contribution of DUB activity in STING dimer inhibition as Sun et al.
demonstrated that the dimer form of STING is ubiquitinated (2009). Whether or not
inhibition of STING dimer is necessary for IFN antagonism is still unclear. Mere
association of PLPs with STING could be sufficient to inhibit STING‐mediated activation
of IRF‐3, which could be how the catalytic cysteine mutant is able to antagonize the
activation of type I IFNs independently of DUB activity.
The effect of ISGylation of cellular proteins on the antiviral response is far less
understood. It is known that ISG15 conjugation is required for protection against lethal
Sindbis infection of IFN‐α/β receptor knock‐out mice (Frias‐Staheli, et al., 2007). Also,
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ISGylation has been shown to influence the activation of the JAK/STAT pathway involved
in type I IFN signaling (Malakhova and Zhang, 2008). Intriguingly, IRF‐3 also undergoes
ISGylation during viral infections, which was found to enhance innate antiviral responses
by inhibiting virus‐induced IRF‐3 degradation (Lu, et al., 2006). HCoV‐NL63 PLP2 globally
deconjugates ISG15 similar to Ub, and this activity depends on the catalytic sites of
PLP2. Furthermore, PLP2‐TM can deISGylate IRF‐3 (Sun et al., manuscript in
preparation). The contribution of this activity remains to be fully explored.
Many viruses have been shown to inhibit the transcriptional activity of IRF‐3 in a
wide variety of ways (Bowie and Unterholzner, 2008; Honda and Taniguchi, 2006; Ozato,
et al., 2007). Some viruses inhibit IRF‐3 phosphorylation, dimerization, and/or
translocation to the nucleus. Others can induce IRF‐3 degradation or sequester the
transcription factor (Chen, et al., 2007a; Higgs, et al., 2008). The mechanism of
inhibition that can lead to these phenotypes can occur directly on IRF‐3 or may affect
any of the vast array of proteins upstream of IRF‐3 in the type I IFN induction cascade.
For example, the VP35 protein of Ebola Zaire virus (EBOV) has been shown to impact
IRF‐3 activity by binding dsRNA, thus preventing detection by RIG‐I (Basler, et al., 2003;
Basler, et al., 2000). In addition, VP35 was shown to interact with Ubc9 (SUMO E2
enzyme), PIAS1 (SUMO E3 ligase), and IRF‐7 leading to SUMOylation of IRF‐7 and
transcriptional repression of the IFN‐β promoter (Chang, et al., 2009). Respiratory
syncytial virus (RSV) encodes two proteins, NS1 and NS2, which inhibit the activity of
IRF‐3. It was reported that these proteins reduce the expression of key kinases
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involved in IRF‐3 phosphorylation (TRAF3 and IKKε), but how NS1 and NS2 induce TRAF3
and IKKε degradation is still unclear (Swedan, et al., 2009).
Using human airway epithelial cells, which represent a cell culture model for
respiratory infection, it was determined that IFN‐β release induced by HCoV‐NL63
infection was weak but measurable (Clementz, et al., 2010). This finding is similar to the
weak IFN induction by the far more pathogenic human coronavirus SARS‐CoV suggesting
that antagonism of type I IFN is a common trait of coronavirus infection (Devaraj, et al.,
2007; Roth‐Cross, et al., 2007; Spiegel, et al., 2006). In addition to PLpro, SARS‐CoV
encodes several other IFN antagonists. ORF 3b, ORF 6, and nucleocapsid inhibit type I
IFN induction via inhibition of IRF‐3 phosphorylation and its subsequent nuclear
translocation (Kopecky‐Bromberg, et al., 2007). M protein has been shown to disrupt
the TRAF3‐TANK‐TBK‐1‐IKKε kinase complex that phosphorylates IRF‐3 (Siu, et al., 2009).
ORF 6 and nsp1 have been shown to inhibit IFN signaling by interfering with the activity
of STAT1 (Frieman, et al., 2007; Kamitani, et al., 2006; Narayanan, et al., 2008). Mouse
hepatitis virus also encodes several IFN antagonists including nsp1, nucleocapsid, and
PLP2 (Roth‐Cross, et al., 2007; Ye, et al., 2007; Zheng, et al., 2008). Thus, there is clear
evolutionary pressure to encode and maintain multiple IFN antagonists, many of which
act toward inhibiting IRF‐3. It has yet to be determined if nsp1 and nucleocapsid from
HCoV‐NL63 are IFN antagonists as well.
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In order for IRF‐3 to influence gene expression, the transcription factor must
translocate to the nucleus. It has been shown that SARS‐CoV PLpro can inhibit IRF‐3
nuclear translocation induced by SeV (Devaraj, et al., 2007). Likewise, HCoV‐NL63 PLP2
can inhibit both N‐RIG and STING‐induced translocation of IRF‐3 to the nucleus. An
association between the PLPs and IRF‐3 has been shown by co‐immunoprecipitation;
however, current data suggests that PLpro and IRF‐3 do not directly interact (Devaraj, et
al., 2007; Frieman, et al., 2009). Thus, the PLPs are inhibiting some other cellular factor
that associates with IRF‐3. STING was shown to constitutively interact with IRF‐3
(Zhong, et al., 2008). Co‐immunoprecipitation experiments demonstrate that STING and
PLPs associate, which could explain the observed association of PLPs with IRF‐3. Future
experiments are needed to determine if the interaction between PLPs and STING is
direct. Gel shift assays using purified proteins are complicated by the fact that both
proteins are integral membrane proteins. The soluble forms of the PLPs are IFN
antagonists and can be purified; however, the soluble C‐terminal domain of STING
cannot activate IRF‐3 and does not associate with the soluble PLPs via co‐
immunoprecipitation. Perhaps other assays like ALPHA screen could be employed to
address this important issue.
It has been shown that type I IFNs are not significantly upregulated in SARS‐CoV
infected patients; however, SARS‐CoV can induce the production of IFN‐α from
plasmacytoid dendritic cells (pDCs) despite a low level of productive infection
(Castilletti, et al., 2005; Reghunathan, et al., 2005). These observations suggest that
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SARS‐CoV IFN antagonists may have differential effects on the IRFs. IRF‐7 is highly and
constitutively expressed in pDCs and can stimulate the production of IFN‐α in the
absence of an IFN‐β‐mediated feedback loop (Barchet, et al., 2002; Honda, et al., 2005;
Izaguirre, et al., 2003). Furthermore, Cervantes‐Barragan et al. demonstrated that
efficient control of MHV infection in mice is mediated by an early and robust induction
of IFN‐α specifically by pDCs in a TLR‐7‐ dependent manner (2007). Future studies are
needed to address whether the known IFN antagonists of SARS‐CoV that effectively
inhibit IRF‐3 activity can also antagonize the activity of IRF‐7.
The data presented in this study draw significant parallels between the single
papain‐like protease of SARS‐CoV PLpro and the second papain‐like protease of HCoV‐
NL63 PLP2. Despite modest sequence identity (~19%), these two proteases have similar
enzymatic activities and can inhibit type I IFN induction independent of catalytic activity.
Since coronavirus PLpro/PLP2 domains are required for viral replication, they are
attractive targets for antiviral therapeutics. Indeed, inhibitors of SARS‐CoV PLpro have
been shown to block virus replication (Ratia, et al., 2008). Though less pathogenic than
SARS‐CoV, HCoV‐NL63 causes significant morbidity in children, the elderly, and immune‐
compromised individuals and has been shown to be an etiological agent causing croup
(van der Hoek, et al., 2005; van der Hoek, et al., 2006). Coronaviruses are now
appreciated as the second leading cause of common cold behind the rhinoviruses
(Fields, et al., 2007). In addition, we now recognize that bats and other mammals can
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serve as reservoirs for potentially emerging pandemic coronaviruses (Lau, et al., 2005;
Li, et al., 2005b). Thus, further studies of these multifunctional coronavirus PLPs are
needed to determine if both protease inhibitors and blockers of interferon antagonism
can be developed to reduce replication and pathogenesis of human and zoonotic
coronaviruses.

APPENDIX
MASS SPECTROMETRY RESULTS WITH PLpro‐HALO
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MASS SPECTROMETRY IDENTIFICATION CRITERIA
Database Searching
MS/MS samples were analyzed using Sequest (ThermoFinnigan, San Jose, CA;
version 27, rev. 12) and X! Tandem (www.thegpm.org; version 2007.01.01.1). X! Tandem
was set up to search a subset of the ipi.HUMAN.v3.27 database also assuming trypsin.
Sequest was set up to search the ipi.HUMAN.v3.27 database (unknown version, 67528
entries) assuming the digestion enzyme trypsin. Sequest and X! Tandem were searched
with a fragment ion mass tolerance of 0.50 Da and a parent ion tolerance of 1.5 Da.
Oxidation of methionine and iodoacetamide derivative of cysteine were specified in
Sequest and X! Tandem as variable modifications.

Criteria For Protein Identification
Scaffold (version Scaffold_2_04_01, Proteome Software Inc., Portland, OR) was
used to validate MS/MS based peptide and protein identifications. Peptide
identifications were accepted if they exceeded specific database search engine
thresholds. Sequest identifications required at least deltaCn scores of greater than 0.08
and XCorr scores of greater than 1.8, 2.5, 3.5 for singly, doubly, triply charged peptides.
X! Tandem identifications required at least ‐Log(Expect Scores) scores of greater than
3.0. Protein identifications were accepted if they contained at least 1 identified
peptides. Proteins that contained similar peptides and could not be differentiated based
on MS/MS analysis alone were grouped to satisfy the principles of parsimony.
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